Renal Cell Carcinoma

Cancer MONDO:0005086 Pathograph 11 Show in embeddings browser Kidney Cancer

Renal cell carcinoma is the most common form of kidney cancer arising from renal epithelial cells.

Ask OpenScientist

Ask a research question about Renal Cell Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

10
Pathophys.
5
Phenotypes
5
Gaps
11
Pathograph
4
Genes
5
Medical Actions
4
Datasets
23
References
2
Deep Research
🏷

Classifications

ICD-O Morphology
Carcinoma
Harrison's Part
ONCOLOGY HEMATOLOGY
?

Discussions and Knowledge Gaps

5
PRR15 (Proline-rich 15) was recently reported to suppress renal cell carcinoma progression by promoting cuproptosis via an NF-κB/FDX1 axis, yet the upstream signals that silence PRR15 during tumorigenesis, the functional hierarchy of the PRR15/NF-κB/FDX1 axis, and the relevance of impaired cuproptosis to therapy resistance remain unknown. Which signals trigger PRR15 loss, is PRR15 a direct or indirect regulator of NF-κB, and is PRR15 loss a driver or passenger event in RCC?
KNOWLEDGE GAP OPEN gap_rcc_prr15_cuproptosis
Attached to
pathophysiology#Renal Epithelial Malignancy pathophysiology#Histologic and Molecular Heterogeneity
Cuproptosis, a copper-dependent regulated cell death, contributes to RCC proliferation, metastasis, and drug-resistance with Ferredoxin 1 (FDX1) as a core regulator. Ma et al. (2026) report that PRR15 promotes cuproptosis and mitochondrial damage in RCC cells and that PRR15 silencing activates NF-κB, which represses FDX1 and blocks cuproptosis, increasing tumor invasiveness. However, the upstream events that drive PRR15 loss in developing RCC are not defined, leaving open whether PRR15 silencing is a tumor-initiating driver or a passenger consequence of malignant transformation. It is also unresolved whether PRR15 regulates NF-κB directly or through intermediate effectors, and whether the same axis operates across the histologic and molecular subtypes of RCC. Finally, the contribution of cuproptosis evasion to resistance against conventional and targeted RCC therapies is unknown. Resolving these gaps would clarify whether the PRR15/NF-κB/FDX1 axis is a tractable therapeutic target and a biomarker of RCC aggressiveness.
Proposed experiments
Identify upstream triggers and driver/passenger status of PRR15 silencing
integrative molecular profiling with functional perturbation Relation: this experiment is of type this experiment type This experiment is of type integrative molecular profiling with functional perturbation.
exp_rcc_prr15_silencing_triggers
Profile PRR15 expression, promoter methylation, copy-number, and mutation status across primary RCC tumors and matched normal kidney, stratified by histologic and molecular subtype. Combine with engineered restoration or knockout of PRR15 in RCC cell lines and orthotopic xenografts to test whether PRR15 loss is sufficient to initiate or accelerate malignant progression versus arising downstream of established transformation, and whether candidate upstream signals (e.g., inflammatory cytokine exposure, epigenetic silencing) suppress PRR15.
Readouts
PRR15 silencing mechanism across subtypes
pathophysiology#Histologic and Molecular Heterogeneity
Quantify PRR15 expression, promoter methylation, and genomic alterations across RCC subtypes to determine the dominant silencing mechanism and whether it is subtype-specific.
bisulfite sequencing Relation: this readout is measured by this assay This readout is measured by bisulfite sequencing. RNA sequencing Relation: this readout is measured by this assay This readout is measured by RNA sequencing.
Direction: NEGATIVE
Tumorigenic consequence of PRR15 manipulation
pathophysiology#Renal Epithelial Malignancy
Measure proliferation, invasion, and metastatic burden after PRR15 restoration or knockout to test whether PRR15 loss is a driver of malignant progression.
orthotopic xenograft tumor growth assay Relation: this readout is measured by this assay This readout is measured by orthotopic xenograft tumor growth assay. transwell invasion assay Relation: this readout is measured by this assay This readout is measured by transwell invasion assay.
Direction: POSITIVE
Decision criterion
PRR15 loss is supported as a driver if its restoration suppresses, and its knockout enhances, tumor proliferation/invasion in vivo, and if a reproducible upstream silencing mechanism (e.g., promoter hypermethylation) is identified in primary tumors with low PRR15. A predominantly passenger role is supported if PRR15 manipulation does not alter tumor behavior despite axis perturbation.
Would support
pathophysiology#Renal Epithelial Malignancy pathophysiology#Histologic and Molecular Heterogeneity
Show evidence (3 references)
PMID:41673093 SUPPORT In Vitro
"PRR15 promotes cuproptosis and mitochondrial damage in RCC cells"
Establishes the cell-based finding that PRR15 promotes cuproptosis and mitochondrial damage in RCC cells, motivating the gap around how PRR15 is silenced and its driver/passenger status.
PMID:41673093 SUPPORT Model Organism
"inhibits tumor proliferation and metastasis, as demonstrated in vivo"
Reports the in vivo (xenograft) tumor-suppressive effect of PRR15, separating the animal-model evidence for tumor suppression from the cell-based cuproptosis mechanism.
PMID:41673093 SUPPORT In Vitro
"When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately blocking the cuproptosis process and increasing tumor invasiveness."
Defines the PRR15/NF-κB/FDX1 axis whose upstream triggers and direct-versus- indirect mechanism remain the central knowledge gap.
What upstream signals or mutations trigger PRR15 silencing during RCC development and progression?
KNOWLEDGE GAP OPEN prr15_upstream_triggers
Attached to
pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
The study demonstrates that PRR15 loss is associated with RCC progression and altered NF-κB/FDX1 cuproptosis signaling. However, the cellular or molecular events that trigger PRR15 silencing remain unknown. Identifying these upstream triggers would clarify whether PRR15 loss is a driver mutation, a passenger consequence of other RCC-initiating events, or a context-dependent response to specific RCC subtypes or microenvironmental pressures.
Show evidence (1 reference)
PMID:41673093 SUPPORT
"However, the role of PRR15 in cuproptosis and its molecular mechanisms remain unknown."
The gap statement directly from the paper indicates the unknown nature of PRR15 upstream regulation and mechanistic roles.
Is PRR15 a direct NF-κB inhibitor or does it regulate NF-κB signaling through intermediate mechanisms?
KNOWLEDGE GAP OPEN prr15_nfkb_direct_indirect
Attached to
pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
The regulatory relationship between PRR15 and NF-κB pathway activation is incompletely characterized at the molecular level. PRR15 could directly inhibit NF-κB signaling via protein-protein interaction, suppress it indirectly through effects on upstream activators, or modulate it through other signaling modules. Mechanistic clarity would support rational therapeutic targeting strategies and predict which RCC contexts would benefit from PRR15 restoration or NF-κB inhibition.
Show evidence (1 reference)
PMID:41673093 SUPPORT
"This study reveals for the first time the regulatory mechanism of the PRR15/NF-κB/FDX1 axis in cuproptosis in RCC, providing a new strategy for the treatment of RCC patients."
The authors emphasize this is the first mechanistic characterization of the PRR15-NF-κB-FDX1 axis, indicating important details remain unresolved.
Does PRR15-mediated cuproptosis suppression contribute to resistance against conventional and targeted RCC therapies?
KNOWLEDGE GAP OPEN prr15_therapy_resistance
Attached to
pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
Given that cuproptosis blockade promotes tumor invasiveness and drug resistance formation in RCC, it is unclear whether PRR15 loss-driven cuproptosis impairment specifically confers resistance to cytotoxic therapies, VEGF/HIF-2α-targeted inhibitors, immunotherapy, or multi-targeted combinations. Understanding this relationship would refine patient stratification and treatment selection, potentially guiding rational combination therapies that restore cuproptosis via PRR15 restoration or direct cuproptosis inducers.
Show evidence (1 reference)
PMID:41673093 SUPPORT
"Cuproptosis is involved in the proliferation, metastasis, and drug resistance formation development of renal cell carcinoma (RCC) by regulating lipid metabolism and oxidative stress levels in the tumor microenvironment, with Ferredoxin 1 (FDX1) as a core regulator."
The abstract identifies cuproptosis dysfunction as relevant to drug resistance formation, but the PRR15-specific contribution to resistance against specific therapy classes is not addressed.
Does gut microbiota composition causally determine immune checkpoint inhibitor response in metastatic renal cell carcinoma, or does it track a host immune state set by something else? In the only randomized test to date, adding the live biotherapeutic CBM588 to nivolumab-ipilimumab was followed by a large progression-free survival difference while the trial's microbiome primary endpoint went unmet, so no measured microbial change currently explains the clinical effect, and the taxa, metabolites, and immune steps that would connect a gut community to intratumoral checkpoint sensitivity remain unidentified.
KNOWLEDGE GAP OPEN gap_mrcc_gut_microbiota_checkpoint_response
Attached to
pathophysiology#Immune Microenvironment and Checkpoint Sensitivity pathophysiology#Immune Evasion treatments#Immune Checkpoint Inhibitor Combination Therapy
This entry models checkpoint sensitivity as a property of the tumor immune microenvironment with no host-external input. A candidate input exists: gut microbiota composition is repeatedly reported as a correlate of checkpoint inhibitor efficacy across tumor types, and in metastatic renal cell carcinoma specifically, a randomized phase 1 trial of nivolumab-ipilimumab with or without CBM588 reported a median progression-free survival of 12.7 versus 2.5 months favouring the supplemented arm. The mechanistic problem is that the same trial detected no significant change in Bifidobacterium spp. or in Shannon diversity - the measurement that was supposed to carry the mechanism. A benefit whose proposed mediator did not move leaves three live possibilities the current data cannot separate: an unmeasured microbial or metabolite change, a microbiota-independent effect of the product, or a chance result in a 30-patient open-label study. Until one is established, curating a gut-microbiota node upstream of checkpoint sensitivity would assert a causal edge the evidence does not support. The cross-disease review that prompted this discussion makes the same point structurally: gut composition is emerging as a predictive marker, but the field's primary obstacle is a lack of methodological standardization that generates observational inconsistency and complicates causal inference.
Proposed experiments
Mediation-powered randomized live-biotherapeutic trial with paired stool and tumor immune profiling
randomized controlled trial with causal mediation analysis Relation: this experiment is of type this experiment type This experiment is of type randomized controlled trial with causal mediation analysis.
exp_mrcc_microbiota_checkpoint_mediation_trial
Repeat the CBM588 randomization at a sample size powered for mediation rather than for a single-taxon abundance endpoint, in treatment-naive metastatic renal cell carcinoma receiving nivolumab-ipilimumab. Collect paired longitudinal stool shotgun metagenomes and fecal metabolomes together with on-treatment tumor biopsies, and test formally whether any microbial or metabolite feature mediates the progression-free survival difference. Include a heat-inactivated product arm to separate live colonization from formulation and placebo effects.
Readouts
Microbial or metabolite mediator of the progression-free survival difference
pathophysiology#Immune Microenvironment and Checkpoint Sensitivity
Fraction of the progression-free survival difference attributable to a prespecified microbial taxon or fecal metabolite, estimated by causal mediation analysis over paired longitudinal samples.
shotgun metagenomic sequencing Relation: this readout is measured by this assay This readout is measured by shotgun metagenomic sequencing. untargeted fecal metabolomics Relation: this readout is measured by this assay This readout is measured by untargeted fecal metabolomics.
Intratumoral effector T cell infiltration on treatment
pathophysiology#Immune Evasion
Change in CD8-positive effector T cell density and exhaustion-marker expression in on-treatment biopsies, compared between the supplemented and control arms.
multiplex immunofluorescence Relation: this readout is measured by this assay This readout is measured by multiplex immunofluorescence. single-cell RNA sequencing Relation: this readout is measured by this assay This readout is measured by single-cell RNA sequencing.
Direction: INCREASED
Decision criterion
A gut-microbiota input to checkpoint sensitivity is supported if a microbial or metabolite feature significantly mediates the progression-free survival difference AND that feature tracks with increased intratumoral effector T cell infiltration. It is not supported if the clinical benefit reproduces in the heat-inactivated arm, or if no measured microbial feature mediates it - in which case the effect belongs outside the microbiota axis and the trial result should be treated as unexplained.
Would support
pathophysiology#Immune Microenvironment and Checkpoint Sensitivity
Recorded from monarch-initiative/dismech#6383. Originally attached to the former Metastatic_Renal_Cell_Carcinoma entry (folded into this entry per design decisions §3a) because checkpoint sensitivity and checkpoint-inhibitor combination therapy are modeled on those nodes, and the randomized evidence is in treatment-naive metastatic disease. The two PMID:42426614 items carry `evidence_source: OTHER` because that publication is a narrative review making a field-level synthesis claim rather than reporting primary data; see monarch-initiative/dismech#8184.
Show evidence (5 references)
PMID:35228755 SUPPORT Human Clinical
"PFS was significantly longer in patients receiving nivolumab-ipilimumab with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15, 95% confidence interval 0.05-0.47, P = 0.001)."
The clinical signal that makes a microbiota input to checkpoint response worth modeling at all in this disease.
PMID:35228755 SUPPORT Human Clinical
"The primary endpoint to compare the relative abundance of Bifidobacterium spp. at baseline and at 12 weeks was not met, and no significant differences in Bifidobacterium spp. or Shannon index associated with the addition of CBM588 to nivolumab-ipilimumab were detected."
The core of the gap: the proposed microbial mediator did not measurably change, so the trial does not identify a mechanism linking the product to the survival difference.
PMID:35228755 SUPPORT Human Clinical
"Larger studies are warranted to confirm this clinical observation and elucidate the mechanism of action and the effects on microbiome and immune compartments."
The investigators themselves treat both the clinical effect and its mechanism as unconfirmed, which is the gap recorded here.
+ 2 more references
⚙

Pathophysiology

10
Renal Epithelial Malignancy
Malignant transformation of renal epithelial cells gives rise to renal cell carcinoma with diverse molecular subtypes.
Show evidence (1 reference)
PMID:28898679 SUPPORT
"The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC)."
The abstract identifies RCC as arising from renal epithelium.
Histologic and Molecular Heterogeneity
Renal cell carcinoma comprises multiple histological and molecular subtypes, reflecting heterogeneous biology.
Show evidence (1 reference)
PMID:28898679 SUPPORT
"This entity comprises different histological and molecular subtypes."
The abstract notes RCC heterogeneity across histologic and molecular subtypes.
Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
Cuproptosis is a copper-dependent form of regulated cell death that acts as a tumor suppressor in RCC. Ferredoxin 1 (FDX1) serves as a core regulator of cuproptosis and its associated mitochondrial dysfunction. PRR15 (Proline-rich 15) promotes cuproptosis through a regulatory axis, but during RCC development, PRR15 is silenced. This silencing activates NF-κB signaling, which represses FDX1 expression, blocking cuproptosis and promoting tumor invasiveness and metastasis. The evasion of cuproptosis contributes to RCC progression by allowing tumor cells to escape this cell-death pathway while maintaining enhanced lipid metabolism and altered oxidative stress regulation in the tumor microenvironment.
renal carcinoma cell CL:0002518 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves renal carcinoma cell, annotated with kidney epithelial cell (CL:0002518). CL:0002518 is a cell type from the Cell Ontology.
PRR15 hgnc:22310 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased PRR15 (hgnc:22310). hgnc:22310 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED FDX1 hgnc:3638 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased FDX1 (hgnc:3638). hgnc:3638 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
cuproptosis GO:0160119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cuproptosis (GO:0160119). GO:0160119 is a biological process from the Gene Ontology. ↓ DECREASED canonical NF-kappaB signal transduction GO:0007249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased canonical NF-kappaB signal transduction (GO:0007249). GO:0007249 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Renal Epithelial Malignancy Evasion of cuproptosis through PRR15 silencing and FDX1 repression allows transformed renal epithelial cells to escape copper-dependent cell death, increasing tumor invasiveness and metastatic progression.
Show evidence (3 references)
PMID:41673093 SUPPORT In Vitro
"PRR15 promotes cuproptosis and mitochondrial damage in RCC cells and inhibits tumor proliferation and metastasis, as demonstrated in vivo and in vitro. When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately..."
The study demonstrates that PRR15 loss leads to NF-κB activation and FDX1 suppression, blocking cuproptosis and promoting RCC progression.
PMID:41673093 SUPPORT Model Organism
"inhibits tumor proliferation and metastasis, as demonstrated in vivo"
In vivo studies in RCC xenografts demonstrate that PRR15-mediated cuproptosis suppresses tumor progression.
PMID:41673093 SUPPORT In Vitro
"When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately blocking the cuproptosis process and increasing tumor invasiveness."
Demonstrates the PRR15/NF-κB/FDX1 axis that controls cuproptosis evasion during RCC development.
VHL Inactivation
Biallelic VHL inactivation (somatic mutation, deletion, or promoter methylation) is the initiating lesion in most clear cell RCC, removing the E3 ligase adapter that normally targets HIF-α subunits for proteasomal degradation.
proteasome-mediated VHL-dependent degradation of HIF-α GO:0043161 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased proteasome-mediated VHL-dependent degradation of HIF-α, annotated with proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161). GO:0043161 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Renal Epithelial Malignancy Biallelic VHL loss is the initiating lesion of the clear cell renal epithelial malignancy this entry models.
HIF Transcription Factor Stabilization Loss of VHL-mediated ubiquitination prevents HIF-α degradation, allowing HIF accumulation.
Show evidence (1 reference)
PMID:37085424 SUPPORT Human Clinical
"These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1; copy number variations; transcriptomic multigene signatures; and specific immune cell populations."
This supports somatic VHL mutation as a defining genomic alteration in clear cell RCC.
HIF Transcription Factor Stabilization
Loss of functional pVHL prevents oxygen-dependent ubiquitination of HIF-α, producing constitutively stabilized HIF transcription factors that activate hypoxia-response programs even under normoxic conditions.
response to hypoxia GO:0001666 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to hypoxia (GO:0001666). GO:0001666 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
VEGF-Dependent Angiogenesis Stabilized HIF drives transcription of VEGF and other angiogenic target genes.
Show evidence (1 reference)
PMID:36831657 SUPPORT Other
"Loss of pVHL function results in elevated levels of HIF-α due to increased stability, leading to RCC progression."
This directly supports HIF-α protein stabilization as the immediate consequence of VHL loss in ccRCC.
VEGF-Dependent Angiogenesis
HIF activation drives VEGF-rich angiogenesis, producing the hypervascular phenotype of metastatic RCC and explaining the durable relevance of VEGF-targeted therapy.
angiogenesis GO:0001525 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased angiogenesis (GO:0001525). GO:0001525 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Tumor Cell Invasion The hypervascular phenotype VEGF drives supplies the neovasculature that invading tumour cells enter, linking the VHL-HIF axis to dissemination.
Show evidence (1 reference)
PMID:39670660 SUPPORT Other
"By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis."
This supports the HIF-2α → angiogenesis transcriptional program as a druggable axis in clear cell RCC.
Tumor Cell Invasion
RCC cells acquire invasive capacity through EMT-like programs and stromal interactions, enabling local tissue invasion and entry into the vasculature.
epithelial to mesenchymal transition GO:0001837 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased epithelial to mesenchymal transition (GO:0001837). GO:0001837 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hematogenous Dissemination Invading tumor cells enter the venous vasculature and seed distant sites, especially lung and bone.
Show evidence (1 reference)
PMID:36646679 SUPPORT Model Organism
"In addition, SERPINE2 could activate the epithelial-mesenchymal transition pathway."
EMT-pathway activation by a RCC-enriched factor supports EMT as the mechanistic basis for tumor cell acquisition of invasive capacity in mRCC.
Hematogenous Dissemination
After local invasion, RCC cells enter venous vasculature and spread hematogenously, with a strong tropism for lung and bone.
cell migration GO:0016477 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell migration (GO:0016477). GO:0016477 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:36646679 SUPPORT Model Organism
"SERPINE2 overexpression dramatically promoted RCC cell metastasis both in vitro and in vivo."
In vivo demonstration that a RCC-expressed factor drives metastatic dissemination of tumor cells directly supports hematogenous spread as a distinct downstream step from local invasion.
Immune Microenvironment and Checkpoint Sensitivity
Metastatic RCC often remains immunologically active enough to benefit from checkpoint blockade, but clinical benefit is heterogeneous and influenced by pathologic response, genomic context, and immune cell composition.
adaptive immune response GO:0002250 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal adaptive immune response (GO:0002250). GO:0002250 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Immune Evasion Within the lymphocyte-infiltrated but immunosuppressed microenvironment of metastatic RCC, suppressive myeloid populations and exhausted T-cell states allow tumour cells to escape the response that checkpoint blockade seeks to restore.
Show evidence (1 reference)
PMID:41309336 SUPPORT Human Clinical
"Patients with an MPR at nephrectomy had longer PFS and OS."
This supports a clinically meaningful association between immunotherapy-induced pathologic response and survival in mRCC.
Immune Evasion
Despite immunogenic features, metastatic RCC can still evade host immunity through suppressive myeloid populations, exhausted T-cell states, and nonuniform antigenic pressure.
negative regulation of immune response GO:0050777 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of immune response (GO:0050777). GO:0050777 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:36775874 SUPPORT Human Clinical
"High lymphocyte infiltration and immunosuppression characterize the tumor microenvironment (TME) in renal cell carcinoma (RCC)."
This supports that the mRCC tumor microenvironment is dominated by immunosuppressive features despite dense lymphocyte infiltration, consistent with active immune evasion.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Renal Cell Carcinoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Genitourinary 1
Hematuria FREQUENT HP:0000790 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematuria (HP:0000790). HP:0000790 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6625621 SUPPORT
"Hematuria is an important symptom, and in our series 46% of the patients with renal cell carcinomas were conscious of macrohematuria as an initial symptom."
The abstract identifies hematuria as an important presenting symptom of RCC.
Respiratory 1
Dyspnea OCCASIONAL HP:0002094 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dyspnea (HP:0002094). HP:0002094 is a phenotype from the Human Phenotype Ontology.
Constitutional 2
Flank Pain OCCASIONAL HP:0030157 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flank pain (HP:0030157). HP:0030157 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6625621 SUPPORT
"As an initial symptom, a mass was palpable in 8% and flank pain was felt in 13% of the patients with renal cell carcinomas."
The abstract reports flank pain as an initial symptom in RCC patients.
Bone pain FREQUENT HP:0002653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone pain (HP:0002653). HP:0002653 is a phenotype from the Human Phenotype Ontology.
Growth 1
Weight loss FREQUENT HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

4
VHL (Somatic loss of function)
Gene: VHL hgnc:12687 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is VHL (hgnc:12687). hgnc:12687 is a gene from the HUGO Gene Nomenclature Committee.
PBRM1 (Somatic loss of function)
Gene: PBRM1 hgnc:30064 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PBRM1 (hgnc:30064). hgnc:30064 is a gene from the HUGO Gene Nomenclature Committee.
BAP1 (Somatic loss of function)
Gene: BAP1 hgnc:950 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BAP1 (hgnc:950). hgnc:950 is a gene from the HUGO Gene Nomenclature Committee.
SETD2 (Somatic loss of function)
Gene: SETD2 hgnc:18420 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SETD2 (hgnc:18420). hgnc:18420 is a gene from the HUGO Gene Nomenclature Committee.
💊

Medical Actions

5
Radical Nephrectomy
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Surgical removal of the kidney for localized renal cell carcinoma.
Show evidence (1 reference)
PMID:6625621 SUPPORT
"The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy."
The abstract states radical nephrectomy is a basic and reliable treatment.
Targeted Systemic Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Molecularly targeted agents used to treat advanced renal cell carcinoma.
Show evidence (1 reference)
PMID:28898679 SUPPORT
"Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients."
The abstract notes targeted agents as effective therapies for RCC.
Adjuvant Pembrolizumab
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: pembrolizumab NCIT:C106432 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses pembrolizumab (NCIT:C106432). NCIT:C106432 is a therapeutic agent from the NCI Thesaurus.
Adjuvant PD-1 immune checkpoint inhibitor therapy following nephrectomy for localized clear cell renal cell carcinoma at high risk of relapse, based on the KEYNOTE-564 trial.
Show evidence (1 reference)
PMID:39904712 SUPPORT Other
"The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse."
The updated EAU guidelines cite KEYNOTE-564 showing adjuvant pembrolizumab improves disease-free and overall survival in high-risk localized clear cell RCC.
Belzutifan
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: belzutifan NCIT:C135627 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses belzutifan (NCIT:C135627). NCIT:C135627 is a therapeutic agent from the NCI Thesaurus.
HIF-2α inhibitor approved for treating renal cell carcinoma.
Mechanism Target:
INHIBITS HIF Transcription Factor Stabilization — Belzutifan inhibits the HIF-2 alpha program downstream of VHL loss and HIF stabilization.
Show evidence (2 references)
PMID:39926260 SUPPORT
"Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment."
The abstract describes belzutifan approvals for RCC treatment.
DOI:10.1158/1078-0432.ccr-24-1199 SUPPORT Human Clinical
"FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor."
FDA approval summary supports belzutifan as later-line targeted therapy for advanced RCC after checkpoint and VEGF-TKI exposure.
Immune Checkpoint Inhibitor Combination Therapy
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: nivolumab NCIT:C68814 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses nivolumab (NCIT:C68814). NCIT:C68814 is a therapeutic agent from the NCI Thesaurus. pembrolizumab NCIT:C106432 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses pembrolizumab (NCIT:C106432). NCIT:C106432 is a therapeutic agent from the NCI Thesaurus.
First-line systemic treatment for metastatic RCC commonly uses immune checkpoint inhibitor combinations, either ICI-ICI or ICI plus a tyrosine kinase inhibitor, selected by clinical risk and tolerability.
Mechanism Target:
INHIBITS Immune Evasion — Checkpoint blockade targets suppressive immune signaling in the metastatic RCC tumor microenvironment.
Show evidence (2 references)
DOI:10.1007/s00262-023-03621-1 SUPPORT Other
"Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC)."
This systematic review supports ICI-based combinations as a recommended first-line systemic treatment class for mRCC.
PMID:39581661 SUPPORT Other
"Recommended first-line drugs for metastatic clear cell renal carcinoma are combinations of axitinib/pembrolizumab, nivolumab/ipilimumab, nivolumab/cabozantinib, and lenvatinib/pembrolizumab."
The 2024 French AFU guideline names the recommended first-line ICI-ICI and ICI-TKI combinations for metastatic clear cell RCC.
🌍

Environmental Factors

2
Smoking
exposure to tobacco smoking ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Smoking increases RCC risk and may contribute to aggressive disease biology.
Show evidence (1 reference)
PMID:15523697 SUPPORT Human Clinical
"The relative risk (RR) for RCC for ever smokers as compared to lifetime never smokers was 1.38 (95% confidence interval [CI] = 1.27-1.50)"
Meta-analysis of 24 studies quantifies smoking's association with renal cell carcinoma risk.
Obesity
Obesity is a major RCC risk factor and influences inflammatory and metabolic signaling.
Show evidence (1 reference)
PMID:24615287 SUPPORT Human Clinical
"Compared to normal weight, the pooled relative risks and the corresponding 95% confidence intervals of RCC were 1.28(1.24-1.33) for preobesity and 1.77(1.68-1.87) for obesity, respectively"
Dose-response meta-analysis of cohort studies quantifies obesity's association with renal cell carcinoma risk.
🪜

Stages

2
Localized
Disease confined to the kidney or locoregional nodes, where radical or partial nephrectomy with or without adjuvant therapy is potentially curative.
Metastatic
Advanced RCC with dissemination most commonly to lung, bone, liver, and brain. Clear cell biology predominates and is driven by VHL loss, HIF stabilization, intense angiogenesis, and context-dependent immune responsiveness that has made checkpoint blockade a core therapy in modern metastatic RCC.
Folded in from the former Metastatic_Renal_Cell_Carcinoma entry (cancer granularity ladder, design decisions §3a). Lung and bone are common metastatic destinations, but the dominant mechanistic theme is still VHL-HIF-driven angiogenic biology layered with heterogeneous immune responsiveness; the Tumor Cell Invasion and Hematogenous Dissemination pathophysiology nodes carry the stage-specific mechanism content.
Show evidence (1 reference)
PMID:28882737 SUPPORT Human Clinical
"The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively."
Provides a long-term real-world survival estimate for the metastatic stage of RCC.
📊

Related Datasets

4
Gene array analysis of clear cell renal cell carcinoma tissue versus matched normal kidney tissue geo:GSE53757
Microarray dataset of clear cell renal cell carcinoma and matched adjacent normal kidney tissue.
human MICROARRAY n=144
kidney tissue UBERON:0002113 Uberon multi-species anatomy ontology (UBERON) Relation: this dataset samples this sample type This dataset samples kidney tissue, annotated with kidney (UBERON:0002113). UBERON:0002113 is a sample type from the Uberon multi-species anatomy ontology.
Conditions: clear cell renal cell carcinoma adjacent normal kidney tissue
Includes 72 clear cell renal cell carcinoma samples and 72 adjacent normal samples.
A Phase II Trial of High Dose Interleukin-2 and Multi-site Stereotactic Ablative Radiotherapy for Patients with Metastatic Renal Cell Carcinoma ega:EGAS00001003605
Immune-based therapies have improved outcomes for metastatic renal cell carcinoma (mRCC) but there is still a significant margin for improvement. Here, we report the results of a phase II trial combining high dose Interleukin-2 (HD-IL-2) with stereotactic ablative body radiotherapy (SAbR) for patients with metastatic renal cell carcinoma.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Pancreatic tropism of metastatic renal cell carcinoma ega:EGAS00001004208
Renal cell carcinoma (RCC) is characterized by a particularly broad metastatic swath, and enigmatically, when the pancreas is a destination, the disease is associated with improved survival. Intrigued by this observation, we sought to characterize the clinical behavior, therapeutic implications, and underlying biology. While pancreatic metastases (PM) are infrequent, we identified 31 patients across two institutional cohorts and show that improved survival is independent of established prognostic variables, that these tumors are exquisitely sensitive to anti-angiogenic agents and resistant to immune checkpoint inhibitors (ICI), and that they are characterized by a distinctive biology.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Bulk RNAseq gene expression of baseline tumors from metastatic urothelial bladder cancer patients (IMvigor210) and metastatic renal cell carcinoma (IMmotion150) ega:EGAS00001004386
We examined tumors from a large cohort of patients with metastatic urothelial bladder cancer (mUC) and metastatic renal cell carcinoma (mRCC) treated with an anti-PD-L1 agent (atezolizumab) and found that high tumor IL8 gene expression was associated with worse overall survival (OS). We further identified the tumoral immune presence based on Teff signature. We found that high tumor IL8 expression continued to be associated with worse OS even in inflamed tumors in mUC and mRCC.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
{ }

Source YAML

click to show 
name: Renal Cell Carcinoma
creation_date: '2026-02-02T00:16:36Z'
category: Cancer
parents:
- Kidney Cancer
disease_term:
  preferred_term: renal cell carcinoma
  term:
    id: MONDO:0005086
    label: renal cell carcinoma
gene_sets:
- gene_set: MYGENESET:KEGG_RENAL_CELL_CARCINOMA
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG renal cell carcinoma pathway. Metastasis-specific biology is carried by the Tumor Cell Invasion and Hematogenous Dissemination nodes (the former Metastatic_Renal_Cell_Carcinoma entry was folded in).
description: >-
  Renal cell carcinoma is the most common form of kidney cancer arising from
  renal epithelial cells.
stages:
- name: Localized
  description: >-
    Disease confined to the kidney or locoregional nodes, where radical or
    partial nephrectomy with or without adjuvant therapy is potentially
    curative.
- name: Metastatic
  description: >-
    Advanced RCC with dissemination most commonly to lung, bone, liver, and
    brain. Clear cell biology predominates and is driven by VHL loss, HIF
    stabilization, intense angiogenesis, and context-dependent immune
    responsiveness that has made checkpoint blockade a core therapy in modern
    metastatic RCC.
  notes: >-
    Folded in from the former Metastatic_Renal_Cell_Carcinoma entry (cancer
    granularity ladder, design decisions §3a). Lung and bone are common
    metastatic destinations, but the dominant mechanistic theme is still
    VHL-HIF-driven angiogenic biology layered with heterogeneous immune
    responsiveness; the Tumor Cell Invasion and Hematogenous Dissemination
    pathophysiology nodes carry the stage-specific mechanism content.
  evidence:
  - reference: PMID:28882737
    reference_title: "Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively.
    explanation: Provides a long-term real-world survival estimate for the metastatic stage of RCC.
pathophysiology:
- name: Renal Epithelial Malignancy
  description: >-
    Malignant transformation of renal epithelial cells gives rise to renal cell
    carcinoma with diverse molecular subtypes.
  evidence:
  - reference: PMID:28898679
    reference_title: "Systemic treatment of renal cell cancer: A comprehensive review."
    supports: SUPPORT
    snippet: "The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC)."
    explanation: The abstract identifies RCC as arising from renal epithelium.
- name: Histologic and Molecular Heterogeneity
  description: >-
    Renal cell carcinoma comprises multiple histological and molecular
    subtypes, reflecting heterogeneous biology.
  evidence:
  - reference: PMID:28898679
    reference_title: "Systemic treatment of renal cell cancer: A comprehensive review."
    supports: SUPPORT
    snippet: "This entity comprises different histological and molecular subtypes."
    explanation: The abstract notes RCC heterogeneity across histologic and molecular subtypes.
- name: Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
  description: >-
    Cuproptosis is a copper-dependent form of regulated cell death that acts as a
    tumor suppressor in RCC. Ferredoxin 1 (FDX1) serves as a core regulator of
    cuproptosis and its associated mitochondrial dysfunction. PRR15 (Proline-rich 15)
    promotes cuproptosis through a regulatory axis, but during RCC development, PRR15
    is silenced. This silencing activates NF-κB signaling, which represses FDX1
    expression, blocking cuproptosis and promoting tumor invasiveness and metastasis.
    The evasion of cuproptosis contributes to RCC progression by allowing tumor cells
    to escape this cell-death pathway while maintaining enhanced lipid metabolism and
    altered oxidative stress regulation in the tumor microenvironment.
  genes:
  - preferred_term: PRR15
    term:
      id: hgnc:22310
      label: PRR15
    modifier: DECREASED
  - preferred_term: FDX1
    term:
      id: hgnc:3638
      label: FDX1
    modifier: DECREASED
  cell_types:
  - preferred_term: renal carcinoma cell
    term:
      id: CL:0002518
      label: kidney epithelial cell
  biological_processes:
  - preferred_term: cuproptosis
    term:
      id: GO:0160119
      label: cuproptosis
    modifier: DECREASED
  - preferred_term: canonical NF-kappaB signal transduction
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
    modifier: INCREASED
  downstream:
  - target: Renal Epithelial Malignancy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Evasion of cuproptosis through PRR15 silencing and FDX1 repression allows
      transformed renal epithelial cells to escape copper-dependent cell death,
      increasing tumor invasiveness and metastatic progression.
  evidence:
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "PRR15 promotes cuproptosis and mitochondrial damage in RCC cells and inhibits tumor proliferation and metastasis, as demonstrated in vivo and in vitro. When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately blocking the cuproptosis process and increasing tumor invasiveness."
    explanation: The study demonstrates that PRR15 loss leads to NF-κB activation and FDX1 suppression, blocking cuproptosis and promoting RCC progression.
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "inhibits tumor proliferation and metastasis, as demonstrated in vivo"
    explanation: In vivo studies in RCC xenografts demonstrate that PRR15-mediated cuproptosis suppresses tumor progression.
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately blocking the cuproptosis process and increasing tumor invasiveness."
    explanation: Demonstrates the PRR15/NF-κB/FDX1 axis that controls cuproptosis evasion during RCC development.
- name: VHL Inactivation
  description: >-
    Biallelic VHL inactivation (somatic mutation, deletion, or promoter methylation)
    is the
    initiating lesion in most clear cell RCC, removing the E3 ligase adapter that
    normally
    targets HIF-α subunits for proteasomal degradation.
  evidence:
  - reference: PMID:37085424
    reference_title: "Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1; copy number variations; transcriptomic multigene signatures; and specific immune cell populations.
    explanation: This supports somatic VHL mutation as a defining genomic alteration in clear cell RCC.
  biological_processes:
  - preferred_term: proteasome-mediated VHL-dependent degradation of HIF-α
    modifier: DECREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  downstream:
  - target: Renal Epithelial Malignancy
    description: >-
      Biallelic VHL loss is the initiating lesion of the clear cell renal epithelial
      malignancy this entry models.
  - target: HIF Transcription Factor Stabilization
    description: Loss of VHL-mediated ubiquitination prevents HIF-α degradation, allowing HIF accumulation.
- name: HIF Transcription Factor Stabilization
  description: >-
    Loss of functional pVHL prevents oxygen-dependent ubiquitination of HIF-α, producing
    constitutively stabilized HIF transcription factors that activate hypoxia-response
    programs even under normoxic conditions.
  evidence:
  - reference: PMID:36831657
    reference_title: "Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Loss of pVHL function results in elevated levels of HIF-α due to increased stability, leading to RCC progression.
    explanation: This directly supports HIF-α protein stabilization as the immediate consequence of VHL loss in ccRCC.
  biological_processes:
  - preferred_term: response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0001666
      label: response to hypoxia
  downstream:
  - target: VEGF-Dependent Angiogenesis
    description: Stabilized HIF drives transcription of VEGF and other angiogenic target genes.
- name: VEGF-Dependent Angiogenesis
  description: >-
    HIF activation drives VEGF-rich angiogenesis, producing the hypervascular phenotype
    of
    metastatic RCC and explaining the durable relevance of VEGF-targeted therapy.
  evidence:
  - reference: PMID:39670660
    reference_title: "Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.
    explanation: This supports the HIF-2α → angiogenesis transcriptional program as a druggable axis in clear cell RCC.
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  downstream:
  - target: Tumor Cell Invasion
    description: >-
      The hypervascular phenotype VEGF drives supplies the neovasculature that
      invading tumour cells enter, linking the VHL-HIF axis to dissemination.
- name: Tumor Cell Invasion
  conforms_to: "invasion_and_metastasis#Epithelial-Mesenchymal Transition Activation"
  description: >-
    RCC cells acquire invasive capacity through EMT-like programs and stromal interactions,
    enabling local tissue invasion and entry into the vasculature.
  evidence:
  - reference: PMID:36646679
    reference_title: "Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In addition, SERPINE2 could activate the epithelial-mesenchymal transition pathway.
    explanation: EMT-pathway activation by a RCC-enriched factor supports EMT as the mechanistic basis for tumor cell acquisition of invasive capacity in mRCC.
  biological_processes:
  - preferred_term: epithelial to mesenchymal transition
    modifier: INCREASED
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  downstream:
  - target: Hematogenous Dissemination
    description: Invading tumor cells enter the venous vasculature and seed distant sites, especially lung and bone.
- name: Hematogenous Dissemination
  conforms_to: "invasion_and_metastasis#Circulatory Survival and Extravasation"
  description: >-
    After local invasion, RCC cells enter venous vasculature and spread hematogenously,
    with a strong tropism for lung and bone.
  evidence:
  - reference: PMID:36646679
    reference_title: "Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: SERPINE2 overexpression dramatically promoted RCC cell metastasis both in vitro and in vivo.
    explanation: In vivo demonstration that a RCC-expressed factor drives metastatic dissemination of tumor cells directly supports hematogenous spread as a distinct downstream step from local invasion.
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
- name: Immune Microenvironment and Checkpoint Sensitivity
  description: >-
    Metastatic RCC often remains immunologically active enough to benefit from checkpoint
    blockade, but clinical benefit is heterogeneous and influenced by pathologic response,
    genomic context, and immune cell composition.
  evidence:
  - reference: PMID:41309336
    reference_title: "Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with an MPR at nephrectomy had longer PFS and OS.
    explanation: This supports a clinically meaningful association between immunotherapy-induced pathologic response and survival in mRCC.
  biological_processes:
  - preferred_term: adaptive immune response
    modifier: ABNORMAL
    term:
      id: GO:0002250
      label: adaptive immune response
  downstream:
  - target: Immune Evasion
    description: >-
      Within the lymphocyte-infiltrated but immunosuppressed microenvironment of
      metastatic RCC, suppressive myeloid populations and exhausted T-cell states
      allow tumour cells to escape the response that checkpoint blockade seeks to
      restore.
- name: Immune Evasion
  description: >-
    Despite immunogenic features, metastatic RCC can still evade host immunity through
    suppressive myeloid populations, exhausted T-cell states, and nonuniform antigenic
    pressure.
  evidence:
  - reference: PMID:36775874
    reference_title: "EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: High lymphocyte infiltration and immunosuppression characterize the tumor microenvironment (TME) in renal cell carcinoma (RCC).
    explanation: This supports that the mRCC tumor microenvironment is dominated by immunosuppressive features despite dense lymphocyte infiltration, consistent with active immune evasion.
  biological_processes:
  - preferred_term: negative regulation of immune response
    modifier: INCREASED
    term:
      id: GO:0050777
      label: negative regulation of immune response
phenotypes:
- name: Hematuria
  category: Genitourinary
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  evidence:
  - reference: PMID:6625621
    reference_title: "[Diagnosis and treatment of renal cell carcinoma]."
    supports: SUPPORT
    snippet: "Hematuria is an important symptom, and in our series 46% of the patients with renal cell carcinomas were conscious of macrohematuria as an initial symptom."
    explanation: The abstract identifies hematuria as an important presenting symptom of RCC.
- name: Flank Pain
  category: Genitourinary
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Flank pain
    term:
      id: HP:0030157
      label: Flank pain
  evidence:
  - reference: PMID:6625621
    reference_title: "[Diagnosis and treatment of renal cell carcinoma]."
    supports: SUPPORT
    snippet: "As an initial symptom, a mass was palpable in 8% and flank pain was felt in 13% of the patients with renal cell carcinomas."
    explanation: The abstract reports flank pain as an initial symptom in RCC patients.
- category: Musculoskeletal
  name: Bone pain
  frequency: FREQUENT
  description: Bone metastases cause pain and skeletal-related events.
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
- category: Respiratory
  name: Dyspnea
  frequency: OCCASIONAL
  description: Lung metastases may present with cough or dyspnea.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Constitutional
  name: Weight loss
  frequency: FREQUENT
  description: Weight loss is common in advanced systemic RCC.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
treatments:
- name: Radical Nephrectomy
  description: Surgical removal of the kidney for localized renal cell carcinoma.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:6625621
    reference_title: "[Diagnosis and treatment of renal cell carcinoma]."
    supports: SUPPORT
    snippet: "The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy."
    explanation: The abstract states radical nephrectomy is a basic and reliable treatment.
- name: Targeted Systemic Therapy
  description: Molecularly targeted agents used to treat advanced renal cell carcinoma.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:28898679
    reference_title: "Systemic treatment of renal cell cancer: A comprehensive review."
    supports: SUPPORT
    snippet: "Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients."
    explanation: The abstract notes targeted agents as effective therapies for RCC.
- name: Adjuvant Pembrolizumab
  description: >-
    Adjuvant PD-1 immune checkpoint inhibitor therapy following nephrectomy for
    localized clear cell renal cell carcinoma at high risk of relapse, based on
    the KEYNOTE-564 trial.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
  evidence:
  - reference: PMID:39904712
    reference_title: Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse."
    explanation: The updated EAU guidelines cite KEYNOTE-564 showing adjuvant pembrolizumab improves disease-free and overall survival in high-risk localized clear cell RCC.
- name: Belzutifan
  description: HIF-2α inhibitor approved for treating renal cell carcinoma.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: belzutifan
      term:
        id: NCIT:C135627
        label: Belzutifan
  evidence:
  - reference: PMID:39926260
    reference_title: "Belzutifan for the treatment of renal cell carcinoma."
    supports: SUPPORT
    snippet: "Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment."
    explanation: The abstract describes belzutifan approvals for RCC treatment.
  - reference: DOI:10.1158/1078-0432.ccr-24-1199
    reference_title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
    explanation: FDA approval summary supports belzutifan as later-line targeted therapy for advanced RCC after checkpoint and VEGF-TKI exposure.
  target_mechanisms:
  - target: HIF Transcription Factor Stabilization
    treatment_effect: INHIBITS
    description: Belzutifan inhibits the HIF-2 alpha program downstream of VHL loss and HIF stabilization.
- name: Immune Checkpoint Inhibitor Combination Therapy
  description: >-
    First-line systemic treatment for metastatic RCC commonly uses immune
    checkpoint inhibitor combinations, either ICI-ICI or ICI plus a tyrosine
    kinase inhibitor, selected by clinical risk and tolerability.
  evidence:
  - reference: DOI:10.1007/s00262-023-03621-1
    reference_title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
    explanation: This systematic review supports ICI-based combinations as a recommended first-line systemic treatment class for mRCC.
  - reference: PMID:39581661
    reference_title: "French AFU Cancer Committee Guidelines - Update 2024-2026: Management of kidney cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recommended first-line drugs for metastatic clear cell renal carcinoma are combinations of axitinib/pembrolizumab, nivolumab/ipilimumab, nivolumab/cabozantinib, and lenvatinib/pembrolizumab."
    explanation: The 2024 French AFU guideline names the recommended first-line ICI-ICI and ICI-TKI combinations for metastatic clear cell RCC.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: nivolumab
      term:
        id: NCIT:C68814
        label: Nivolumab
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
  target_mechanisms:
  - target: Immune Evasion
    treatment_effect: INHIBITS
    description: Checkpoint blockade targets suppressive immune signaling in the metastatic RCC tumor microenvironment.
datasets:
- accession: geo:GSE53757
  title: Gene array analysis of clear cell renal cell carcinoma tissue versus matched normal kidney tissue
  description: >-
    Microarray dataset of clear cell renal cell carcinoma and matched adjacent
    normal kidney tissue.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: kidney tissue
    tissue_term:
      preferred_term: kidney
      term:
        id: UBERON:0002113
        label: kidney
  sample_count: 144
  conditions:
  - clear cell renal cell carcinoma
  - adjacent normal kidney tissue
  notes: >-
    Includes 72 clear cell renal cell carcinoma samples and 72 adjacent normal
    samples.
- accession: ega:EGAS00001003605
  title: A Phase II Trial of High Dose Interleukin-2 and Multi-site Stereotactic Ablative Radiotherapy for Patients with Metastatic Renal Cell Carcinoma
  description: Immune-based therapies have improved outcomes for metastatic renal cell carcinoma (mRCC) but there is still a significant margin for improvement. Here, we report the results of a phase II trial combining high dose Interleukin-2 (HD-IL-2) with stereotactic ablative body radiotherapy (SAbR) for patients with metastatic renal cell carcinoma.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001004208
  title: Pancreatic tropism of metastatic renal cell carcinoma
  description: Renal cell carcinoma (RCC) is characterized by a particularly broad metastatic swath, and enigmatically, when the pancreas is a destination, the disease is associated with improved survival. Intrigued by this observation, we sought to characterize the clinical behavior, therapeutic implications, and underlying biology. While pancreatic metastases (PM) are infrequent, we identified 31 patients across two institutional cohorts and show that improved survival is independent of established prognostic variables, that these tumors are exquisitely sensitive to anti-angiogenic agents and resistant to immune checkpoint inhibitors (ICI), and that they are characterized by a distinctive biology.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001004386
  title: Bulk RNAseq gene expression of baseline tumors from metastatic urothelial bladder cancer patients (IMvigor210) and metastatic renal cell carcinoma (IMmotion150)
  description: We examined tumors from a large cohort of patients with metastatic urothelial bladder cancer (mUC) and metastatic renal cell carcinoma (mRCC) treated with an anti-PD-L1 agent (atezolizumab) and found that high tumor IL8 gene expression was associated with worse overall survival (OS). We further identified the tumoral immune presence based on Teff signature. We found that high tumor IL8 expression continued to be associated with worse OS even in inflamed tumors in mUC and mRCC.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Renal Cell Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
references:
- reference: DOI:10.1038/s41420-025-02479-9
  title: The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma
  findings: []
- reference: DOI:10.1038/s41467-023-37211-7
  title: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma
  findings: []
- reference: DOI:10.1038/s41581-023-00800-2
  title: Metabolic alterations in hereditary and sporadic renal cell carcinoma
  findings: []
- reference: DOI:10.1038/s41586-024-07812-3
  title: Mitochondrial complex I promotes kidney cancer metastasis
  findings: []
- reference: DOI:10.1136/jitc-2023-008226
  title: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
  findings: []
- reference: DOI:10.3390/cancers16030601
  title: Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma
  findings: []
- reference: PMID:29656891
  title: 'Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.'
  findings: []
- reference: DOI:10.1007/s00262-023-03621-1
  title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
    supporting_text: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
    evidence:
    - reference: DOI:10.1007/s00262-023-03621-1
      reference_title: Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1007/s40620-024-01984-x
  title: 'Air pollution and kidney cancer risk: a systematic review and meta-analysis'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
    supporting_text: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
    evidence:
    - reference: DOI:10.1007/s40620-024-01984-x
      reference_title: 'Air pollution and kidney cancer risk: a systematic review and meta-analysis'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1016/j.esmoop.2024.102994
  title: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
    supporting_text: 'Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial'
- reference: DOI:10.1038/s41591-024-03086-4
  title: 'Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
    supporting_text: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
    evidence:
    - reference: DOI:10.1038/s41591-024-03086-4
      reference_title: 'Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1038/s42003-024-05772-y
  title: Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
    supporting_text: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
    evidence:
    - reference: DOI:10.1038/s42003-024-05772-y
      reference_title: Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1056/nejmoa2212851
  title: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    supporting_text: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
- reference: DOI:10.1093/oncolo/oyae180
  title: Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
    supporting_text: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
    evidence:
    - reference: DOI:10.1093/oncolo/oyae180
      reference_title: Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1158/1078-0432.ccr-24-1199
  title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
    supporting_text: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
    evidence:
    - reference: DOI:10.1158/1078-0432.ccr-24-1199
      reference_title: 'FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1186/s12916-024-03677-5
  title: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
    supporting_text: 'Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort'
- reference: DOI:10.1186/s12944-024-02138-5
  title: 'Association between metabolic syndrome and kidney cancer risk: a prospective cohort study'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Kidney cancer has become known as a metabolic disease.
    supporting_text: Kidney cancer has become known as a metabolic disease.
    evidence:
    - reference: DOI:10.1186/s12944-024-02138-5
      reference_title: 'Association between metabolic syndrome and kidney cancer risk: a prospective cohort study'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Kidney cancer has become known as a metabolic disease.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.1200/jco.23.01569
  title: 'Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Clinical trials frequently include multiple end points that mature at different times.
    supporting_text: Clinical trials frequently include multiple end points that mature at different times.
    evidence:
    - reference: DOI:10.1200/jco.23.01569
      reference_title: 'Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Clinical trials frequently include multiple end points that mature at different times.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3238/arztebl.m2024.0147
  title: The treatment of metastatic renal cell carcinoma
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: The treatment of metastatic renal cell carcinoma
    supporting_text: The treatment of metastatic renal cell carcinoma
- reference: DOI:10.3346/jkms.2024.39.e293
  title: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
    supporting_text: 'Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database'
- reference: DOI:10.3390/cancers16183234
  title: 'Real-World Survival Outcomes of First-Line Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis from Two Centres in Saudi Arabia'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
    supporting_text: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
    evidence:
    - reference: DOI:10.3390/cancers16183234
      reference_title: 'Real-World Survival Outcomes of First-Line Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis from Two Centres in Saudi Arabia'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3390/cells13010034
  title: Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
    supporting_text: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
    evidence:
    - reference: DOI:10.3390/cells13010034
      reference_title: Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
- reference: DOI:10.3390/cells13110961
  title: 'First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm'
  found_in:
  - Metastatic_Renal_Cell_Carcinoma-deep-research-falcon.md
  findings:
  - statement: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
    supporting_text: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
    evidence:
    - reference: DOI:10.3390/cells13110961
      reference_title: 'First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
      explanation: Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
discussions:
- discussion_id: gap_rcc_prr15_cuproptosis
  prompt: >-
    PRR15 (Proline-rich 15) was recently reported to suppress renal cell
    carcinoma progression by promoting cuproptosis via an NF-κB/FDX1 axis, yet
    the upstream signals that silence PRR15 during tumorigenesis, the functional
    hierarchy of the PRR15/NF-κB/FDX1 axis, and the relevance of impaired
    cuproptosis to therapy resistance remain unknown. Which signals trigger PRR15
    loss, is PRR15 a direct or indirect regulator of NF-κB, and is PRR15 loss a
    driver or passenger event in RCC?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Renal Epithelial Malignancy
  - pathophysiology#Histologic and Molecular Heterogeneity
  rationale: >-
    Cuproptosis, a copper-dependent regulated cell death, contributes to RCC
    proliferation, metastasis, and drug-resistance with Ferredoxin 1 (FDX1) as a
    core regulator. Ma et al. (2026) report that PRR15 promotes cuproptosis and
    mitochondrial damage in RCC cells and that PRR15 silencing activates NF-κB,
    which represses FDX1 and blocks cuproptosis, increasing tumor invasiveness.
    However, the upstream events that drive PRR15 loss in developing RCC are not
    defined, leaving open whether PRR15 silencing is a tumor-initiating driver or
    a passenger consequence of malignant transformation. It is also unresolved
    whether PRR15 regulates NF-κB directly or through intermediate effectors, and
    whether the same axis operates across the histologic and molecular subtypes
    of RCC. Finally, the contribution of cuproptosis evasion to resistance
    against conventional and targeted RCC therapies is unknown. Resolving these
    gaps would clarify whether the PRR15/NF-κB/FDX1 axis is a tractable
    therapeutic target and a biomarker of RCC aggressiveness.
  proposed_experiments:
  - experiment_id: exp_rcc_prr15_silencing_triggers
    name: Identify upstream triggers and driver/passenger status of PRR15 silencing
    description: >-
      Profile PRR15 expression, promoter methylation, copy-number, and mutation
      status across primary RCC tumors and matched normal kidney, stratified by
      histologic and molecular subtype. Combine with engineered restoration or
      knockout of PRR15 in RCC cell lines and orthotopic xenografts to test
      whether PRR15 loss is sufficient to initiate or accelerate malignant
      progression versus arising downstream of established transformation, and
      whether candidate upstream signals (e.g., inflammatory cytokine exposure,
      epigenetic silencing) suppress PRR15.
    experiment_type:
      preferred_term: integrative molecular profiling with functional perturbation
    readouts:
    - name: PRR15 silencing mechanism across subtypes
      target: pathophysiology#Histologic and Molecular Heterogeneity
      description: >
        Quantify PRR15 expression, promoter methylation, and genomic alterations
        across RCC subtypes to determine the dominant silencing mechanism and
        whether it is subtype-specific.
      assays:
      - preferred_term: bisulfite sequencing
      - preferred_term: RNA sequencing
      direction: NEGATIVE
    - name: Tumorigenic consequence of PRR15 manipulation
      target: pathophysiology#Renal Epithelial Malignancy
      description: >
        Measure proliferation, invasion, and metastatic burden after PRR15
        restoration or knockout to test whether PRR15 loss is a driver of
        malignant progression.
      assays:
      - preferred_term: orthotopic xenograft tumor growth assay
      - preferred_term: transwell invasion assay
      direction: POSITIVE
    decision_criterion: >-
      PRR15 loss is supported as a driver if its restoration suppresses, and its
      knockout enhances, tumor proliferation/invasion in vivo, and if a
      reproducible upstream silencing mechanism (e.g., promoter hypermethylation)
      is identified in primary tumors with low PRR15. A predominantly passenger
      role is supported if PRR15 manipulation does not alter tumor behavior
      despite axis perturbation.
    would_support:
    - pathophysiology#Renal Epithelial Malignancy
    - pathophysiology#Histologic and Molecular Heterogeneity
  evidence:
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "PRR15 promotes cuproptosis and mitochondrial damage in RCC cells"
    explanation: >-
      Establishes the cell-based finding that PRR15 promotes cuproptosis and
      mitochondrial damage in RCC cells, motivating the gap around how PRR15 is
      silenced and its driver/passenger status.
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "inhibits tumor proliferation and metastasis, as demonstrated in vivo"
    explanation: >-
      Reports the in vivo (xenograft) tumor-suppressive effect of PRR15,
      separating the animal-model evidence for tumor suppression from the
      cell-based cuproptosis mechanism.
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "When RCC develops, PRR15 silencing activates the nuclear factor kappa-B (NF-κB) signaling pathway, which inhibits FDX1 expression, ultimately blocking the cuproptosis process and increasing tumor invasiveness."
    explanation: >-
      Defines the PRR15/NF-κB/FDX1 axis whose upstream triggers and direct-versus-
      indirect mechanism remain the central knowledge gap.
- discussion_id: prr15_upstream_triggers
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
  prompt: What upstream signals or mutations trigger PRR15 silencing during RCC development and progression?
  rationale: >-
    The study demonstrates that PRR15 loss is associated with RCC progression and altered NF-κB/FDX1 cuproptosis signaling.
    However, the cellular or molecular events that trigger PRR15 silencing remain unknown. Identifying these upstream triggers
    would clarify whether PRR15 loss is a driver mutation, a passenger consequence of other RCC-initiating events, or a
    context-dependent response to specific RCC subtypes or microenvironmental pressures.
  evidence:
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    snippet: "However, the role of PRR15 in cuproptosis and its molecular mechanisms remain unknown."
    explanation: The gap statement directly from the paper indicates the unknown nature of PRR15 upstream regulation and mechanistic roles.
- discussion_id: prr15_nfkb_direct_indirect
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
  prompt: Is PRR15 a direct NF-κB inhibitor or does it regulate NF-κB signaling through intermediate mechanisms?
  rationale: >-
    The regulatory relationship between PRR15 and NF-κB pathway activation is incompletely characterized at the molecular level.
    PRR15 could directly inhibit NF-κB signaling via protein-protein interaction, suppress it indirectly through effects on upstream
    activators, or modulate it through other signaling modules. Mechanistic clarity would support rational therapeutic targeting
    strategies and predict which RCC contexts would benefit from PRR15 restoration or NF-κB inhibition.
  evidence:
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    snippet: "This study reveals for the first time the regulatory mechanism of the PRR15/NF-κB/FDX1 axis in cuproptosis in RCC, providing a new strategy for the treatment of RCC patients."
    explanation: The authors emphasize this is the first mechanistic characterization of the PRR15-NF-κB-FDX1 axis, indicating important details remain unresolved.
- discussion_id: prr15_therapy_resistance
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Cuproptosis via PRR15/NF-κB/FDX1 Axis
  prompt: Does PRR15-mediated cuproptosis suppression contribute to resistance against conventional and targeted RCC therapies?
  rationale: >-
    Given that cuproptosis blockade promotes tumor invasiveness and drug resistance formation in RCC, it is unclear whether
    PRR15 loss-driven cuproptosis impairment specifically confers resistance to cytotoxic therapies, VEGF/HIF-2α-targeted inhibitors,
    immunotherapy, or multi-targeted combinations. Understanding this relationship would refine patient stratification and treatment selection,
    potentially guiding rational combination therapies that restore cuproptosis via PRR15 restoration or direct cuproptosis inducers.
  evidence:
  - reference: PMID:41673093
    reference_title: "PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction."
    supports: SUPPORT
    snippet: "Cuproptosis is involved in the proliferation, metastasis, and drug resistance formation development of renal cell carcinoma (RCC) by regulating lipid metabolism and oxidative stress levels in the tumor microenvironment, with Ferredoxin 1 (FDX1) as a core regulator."
    explanation: The abstract identifies cuproptosis dysfunction as relevant to drug resistance formation, but the PRR15-specific contribution to resistance against specific therapy classes is not addressed.
- discussion_id: gap_mrcc_gut_microbiota_checkpoint_response
  prompt: >-
    Does gut microbiota composition causally determine immune checkpoint
    inhibitor response in metastatic renal cell carcinoma, or does it track a
    host immune state set by something else? In the only randomized test to
    date, adding the live biotherapeutic CBM588 to nivolumab-ipilimumab was
    followed by a large progression-free survival difference while the trial's
    microbiome primary endpoint went unmet, so no measured microbial change
    currently explains the clinical effect, and the taxa, metabolites, and
    immune steps that would connect a gut community to intratumoral checkpoint
    sensitivity remain unidentified.
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Immune Microenvironment and Checkpoint Sensitivity
  - pathophysiology#Immune Evasion
  - treatments#Immune Checkpoint Inhibitor Combination Therapy
  rationale: >-
    This entry models checkpoint sensitivity as a property of the tumor immune
    microenvironment with no host-external input. A candidate input exists: gut
    microbiota composition is repeatedly reported as a correlate of checkpoint
    inhibitor efficacy across tumor types, and in metastatic renal cell
    carcinoma specifically, a randomized phase 1 trial of nivolumab-ipilimumab
    with or without CBM588 reported a median progression-free survival of 12.7
    versus 2.5 months favouring the supplemented arm. The mechanistic problem is
    that the same trial detected no significant change in Bifidobacterium spp.
    or in Shannon diversity - the measurement that was supposed to carry the
    mechanism. A benefit whose proposed mediator did not move leaves three live
    possibilities the current data cannot separate: an unmeasured microbial or
    metabolite change, a microbiota-independent effect of the product, or a
    chance result in a 30-patient open-label study. Until one is established,
    curating a gut-microbiota node upstream of checkpoint sensitivity would
    assert a causal edge the evidence does not support. The cross-disease review
    that prompted this discussion makes the same point structurally: gut
    composition is emerging as a predictive marker, but the field's primary
    obstacle is a lack of methodological standardization that generates
    observational inconsistency and complicates causal inference.
  proposed_experiments:
  - experiment_id: exp_mrcc_microbiota_checkpoint_mediation_trial
    name: Mediation-powered randomized live-biotherapeutic trial with paired stool and tumor immune profiling
    description: >-
      Repeat the CBM588 randomization at a sample size powered for mediation
      rather than for a single-taxon abundance endpoint, in treatment-naive
      metastatic renal cell carcinoma receiving nivolumab-ipilimumab. Collect
      paired longitudinal stool shotgun metagenomes and fecal metabolomes
      together with on-treatment tumor biopsies, and test formally whether any
      microbial or metabolite feature mediates the progression-free survival
      difference. Include a heat-inactivated product arm to separate live
      colonization from formulation and placebo effects.
    experiment_type:
      preferred_term: randomized controlled trial with causal mediation analysis
    readouts:
    - name: Microbial or metabolite mediator of the progression-free survival difference
      target: pathophysiology#Immune Microenvironment and Checkpoint Sensitivity
      description: >-
        Fraction of the progression-free survival difference attributable to a
        prespecified microbial taxon or fecal metabolite, estimated by causal
        mediation analysis over paired longitudinal samples.
      assays:
      - preferred_term: shotgun metagenomic sequencing
      - preferred_term: untargeted fecal metabolomics
    - name: Intratumoral effector T cell infiltration on treatment
      target: pathophysiology#Immune Evasion
      description: >-
        Change in CD8-positive effector T cell density and exhaustion-marker
        expression in on-treatment biopsies, compared between the supplemented
        and control arms.
      assays:
      - preferred_term: multiplex immunofluorescence
      - preferred_term: single-cell RNA sequencing
      direction: INCREASED
    decision_criterion: >-
      A gut-microbiota input to checkpoint sensitivity is supported if a
      microbial or metabolite feature significantly mediates the progression-free
      survival difference AND that feature tracks with increased intratumoral
      effector T cell infiltration. It is not supported if the clinical benefit
      reproduces in the heat-inactivated arm, or if no measured microbial feature
      mediates it - in which case the effect belongs outside the microbiota axis
      and the trial result should be treated as unexplained.
    would_support:
    - pathophysiology#Immune Microenvironment and Checkpoint Sensitivity
  evidence:
  - reference: PMID:35228755
    reference_title: "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PFS was significantly longer in patients receiving nivolumab-ipilimumab
      with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15,
      95% confidence interval 0.05-0.47, P = 0.001).
    explanation: >-
      The clinical signal that makes a microbiota input to checkpoint response
      worth modeling at all in this disease.
  - reference: PMID:35228755
    reference_title: "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary endpoint to compare the relative abundance of Bifidobacterium
      spp. at baseline and at 12 weeks was not met, and no significant
      differences in Bifidobacterium spp. or Shannon index associated with the
      addition of CBM588 to nivolumab-ipilimumab were detected.
    explanation: >-
      The core of the gap: the proposed microbial mediator did not measurably
      change, so the trial does not identify a mechanism linking the product to
      the survival difference.
  - reference: PMID:35228755
    reference_title: "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Larger studies are warranted to confirm this clinical observation and
      elucidate the mechanism of action and the effects on microbiome and immune
      compartments.
    explanation: >-
      The investigators themselves treat both the clinical effect and its
      mechanism as unconfirmed, which is the gap recorded here.
  - reference: PMID:42426614
    reference_title: "Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The composition of the gut microbiota is emerging as a potential
      predictive marker for ICI efficacy, as the enrichment of certain
      beneficial taxa has been linked to favorable outcomes.
    explanation: >-
      Review-level synthesis that the gut-composition-to-checkpoint-response
      link is predictive and emerging rather than mechanistically established.
  - reference: PMID:42426614
    reference_title: "Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A primary challenge is the lack of methodological standardization, which
      generates observational inconsistencies and complicates causal inference.
    explanation: >-
      Names the barrier that keeps this gap open across all three urological
      cancers, and motivates specifying the proposed experiment around formal
      mediation rather than another abundance-endpoint trial.
  notes: >-
    Recorded from monarch-initiative/dismech#6383. Originally attached to the
    former Metastatic_Renal_Cell_Carcinoma entry (folded into this entry per
    design decisions §3a) because checkpoint sensitivity and
    checkpoint-inhibitor combination therapy are modeled on those nodes, and
    the randomized evidence is in treatment-naive metastatic disease. The two
    PMID:42426614 items carry `evidence_source: OTHER` because that publication
    is a narrative review making a field-level synthesis claim rather than
    reporting primary data; see monarch-initiative/dismech#8184.
genetic:
- name: VHL
  gene_term:
    preferred_term: VHL
    term:
      id: hgnc:12687
      label: VHL
  association: Somatic loss of function
  notes: VHL loss is the initiating lesion in most clear cell RCC and underlies HIF addiction.
- name: PBRM1
  gene_term:
    preferred_term: PBRM1
    term:
      id: hgnc:30064
      label: PBRM1
  association: Somatic loss of function
  notes: PBRM1 mutation is common in clear cell RCC and may influence immunotherapy response.
- name: BAP1
  gene_term:
    preferred_term: BAP1
    term:
      id: hgnc:950
      label: BAP1
  association: Somatic loss of function
  notes: BAP1 loss is associated with more aggressive metastatic behavior.
- name: SETD2
  gene_term:
    preferred_term: SETD2
    term:
      id: hgnc:18420
      label: SETD2
  association: Somatic loss of function
  notes: SETD2 mutation contributes to chromatin dysregulation and tumor evolution.
environmental:
- name: Smoking
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  notes: Smoking increases RCC risk and may contribute to aggressive disease biology.
  evidence:
  - reference: PMID:15523697
    reference_title: "Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The relative risk (RR) for RCC for ever smokers as compared to lifetime never smokers was 1.38 (95% confidence interval [CI] = 1.27-1.50)"
    explanation: Meta-analysis of 24 studies quantifies smoking's association with renal cell carcinoma risk.
- name: Obesity
  notes: Obesity is a major RCC risk factor and influences inflammatory and metabolic signaling.
  evidence:
  - reference: PMID:24615287
    reference_title: "Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to normal weight, the pooled relative risks and the corresponding 95% confidence intervals of RCC were 1.28(1.24-1.33) for preobesity and 1.77(1.68-1.87) for obesity, respectively"
    explanation: Dose-response meta-analysis of cohort studies quantifies obesity's association with renal cell carcinoma risk.
classifications:
  icdo_morphology:
    classification_value: Carcinoma
    notes: >-
      Derived from this entry's disease term MONDO:0005086 (renal cell
      carcinoma), whose NCI Thesaurus counterpart NCIT:C9385 (Renal Cell
      Carcinoma) is a descendant of NCIT:C2916 (Carcinoma), the term this enum
      value is bound to. NCIT also places NCIT:C9385 under NCIT:C224634 (Urinary
      System Adenocarcinoma), and ICD-O codes renal cell carcinoma NOS as 8312/3
      within the adenocarcinoma block, so the more specific ``Adenocarcinoma``
      value is defensible; ``Carcinoma`` is recorded here as the conservative
      assignment matching contemporary clinical and WHO usage, which does not
      call renal cell carcinoma an adenocarcinoma.
    evidence:
    - reference: PMID:36831657
      reference_title: "Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The clear cell variant of renal cell carcinoma (ccRCC) is the most common renal epithelial malignancy"
      explanation: >-
        Identifies renal cell carcinoma as an epithelial malignancy, which is
        what the ICD-O carcinoma morphology axis records.
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    notes: >-
      Metastatic renal cell carcinoma is managed as a solid-tumor oncology
      problem (VEGF-directed and checkpoint-inhibitor therapy).
📚

References & Deep Research

References

23
DOI:10.1038/s41420-025-02479-9
The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma
No top-level findings curated for this source.
DOI:10.1038/s41467-023-37211-7
Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma
No top-level findings curated for this source.
DOI:10.1038/s41581-023-00800-2
Metabolic alterations in hereditary and sporadic renal cell carcinoma
No top-level findings curated for this source.
DOI:10.1038/s41586-024-07812-3
Mitochondrial complex I promotes kidney cancer metastasis
No top-level findings curated for this source.
DOI:10.1136/jitc-2023-008226
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
No top-level findings curated for this source.
DOI:10.3390/cancers16030601
Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma
No top-level findings curated for this source.
PMID:29656891
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
No top-level findings curated for this source.
DOI:10.1007/s00262-023-03621-1
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
1 finding
Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC).
"Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC)."
Show evidence (1 reference)
DOI:10.1007/s00262-023-03621-1 SUPPORT Other
"Immune checkpoint inhibitor (ICI)-based combination therapies are the recommended first-line treatment for metastatic renal cell carcinoma (mRCC)."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1007/s40620-024-01984-x
Air pollution and kidney cancer risk: a systematic review and meta-analysis
1 finding
Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution.
"Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution."
Show evidence (1 reference)
DOI:10.1007/s40620-024-01984-x SUPPORT Other
"Although several risk factors of kidney cancer have already been well-addressed, many remain underappreciated, such as chronic exposure to air pollution."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1016/j.esmoop.2024.102994
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
1 finding
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial"
DOI:10.1038/s41591-024-03086-4
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
1 finding
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab.
"Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab."
Show evidence (1 reference)
DOI:10.1038/s41591-024-03086-4 SUPPORT Human Clinical
"Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1038/s42003-024-05772-y
Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma
1 finding
Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
"Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma."
Show evidence (1 reference)
DOI:10.1038/s42003-024-05772-y SUPPORT Human Clinical
"Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1056/nejmoa2212851
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
1 finding
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma"
DOI:10.1093/oncolo/oyae180
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
1 finding
Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years.
"Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years."
Show evidence (1 reference)
DOI:10.1093/oncolo/oyae180 SUPPORT Human Clinical
"Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1158/1078-0432.ccr-24-1199
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
1 finding
FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.
"FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor."
Show evidence (1 reference)
DOI:10.1158/1078-0432.ccr-24-1199 SUPPORT Human Clinical
"FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1186/s12916-024-03677-5
Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort
1 finding
Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort
"Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort"
DOI:10.1186/s12944-024-02138-5
Association between metabolic syndrome and kidney cancer risk: a prospective cohort study
1 finding
Kidney cancer has become known as a metabolic disease.
"Kidney cancer has become known as a metabolic disease."
Show evidence (1 reference)
DOI:10.1186/s12944-024-02138-5 SUPPORT Human Clinical
"Kidney cancer has become known as a metabolic disease."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.1200/jco.23.01569
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
1 finding
Clinical trials frequently include multiple end points that mature at different times.
"Clinical trials frequently include multiple end points that mature at different times."
Show evidence (1 reference)
DOI:10.1200/jco.23.01569 SUPPORT Human Clinical
"Clinical trials frequently include multiple end points that mature at different times."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.3238/arztebl.m2024.0147
The treatment of metastatic renal cell carcinoma
1 finding
The treatment of metastatic renal cell carcinoma
"The treatment of metastatic renal cell carcinoma"
DOI:10.3346/jkms.2024.39.e293
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database
1 finding
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database
"Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database"
DOI:10.3390/cancers16183234
Real-World Survival Outcomes of First-Line Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis from Two Centres in Saudi Arabia
1 finding
Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy.
"Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy."
Show evidence (1 reference)
DOI:10.3390/cancers16183234 SUPPORT Human Clinical
"Metastatic renal cell carcinoma (mRCC) represents a challenging condition characterised by poor prognosis and limited response to chemoradiotherapy."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.3390/cells13010034
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
1 finding
The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
"The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC)."
Show evidence (1 reference)
DOI:10.3390/cells13010034 SUPPORT Other
"The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC)."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.
DOI:10.3390/cells13110961
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm
1 finding
The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years.
"The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years."
Show evidence (1 reference)
DOI:10.3390/cells13110961 SUPPORT Other
"The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years."
Deep research cited this publication as relevant literature for Metastatic Renal Cell Carcinoma.

Deep Research

2
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 23 citations 2026-01-31T17:37:07.263328

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Renal Cell Carcinoma (RCC)
  • MONDO ID: MONDO:0005070
  • Category: Cancer

Pathophysiology Description (Narrative)

Renal cell carcinoma comprises biologically distinct subtypes with shared themes of oxygen/nutrient-sensing deregulation, profound metabolic rewiring, and an immunosuppressive tumor microenvironment. In clear cell RCC (ccRCC), loss of VHL on chromosome 3p stabilizes HIF-α subunits, especially HIF‑2α (EPAS1), driving angiogenesis, glycolysis, lipid storage, and immune escape programs; these changes underlie responsiveness to VEGF pathway inhibitors and, more recently, to direct HIF‑2α antagonism (belzutifan) (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32). Multi-omic and single-cell studies corroborate ccRCC intratumoral heterogeneity, with tumor subpopulations enriched for EMT and inflammation programs and distinct chromatin-accessibility consequences of PBRM1 versus BAP1 mutations (coffey2024metabolicalterationsin pages 30-32). Whole‑genome sequencing of >700 ccRCC further refines driver landscapes and links structural copy alterations and canonical genes (VHL, PBRM1, SETD2, BAP1) to outcomes and immune infiltration, supporting immunotherapy rationales (coffey2024metabolicalterationsin pages 30-32).

Metabolically, ccRCC is a prototype metabolic cancer: in vivo isotope tracing shows suppressed TCA labeling and ETC activity in primary tumors but a metabolic shift toward enhanced TCA flux in metastases; mouse experiments demonstrate that stimulating mitochondrial respiration or NADH recycling promotes metastasis, whereas complex I inhibition suppresses it (bezwada2024mitochondrialcomplexi pages 1-2). High OXPHOS transcriptional programs correlate with resistance to immune checkpoint inhibition; experimentally dampening complex I (Ndufb8 knockdown) reduces hypoxia, increases functional CD8+ T‑cell infiltration, and improves anti‑PD‑L1 efficacy in vivo (tian2024targetingoxidativephosphorylation pages 1-2). Beyond glucose, ccRCC exhibits glutamine dependence, ferroptosis sensitivity controlled by glutathione/GPX4 systems, and extensive lipid/cholesterol rewiring including SR‑BI (SCARB1) upregulation and tryptophan–kynurenine pathway activation that fosters immune suppression (coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 19-21, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 36-38).

In papillary RCC (pRCC), type 1 commonly harbors MET activation, while type 2 includes FH deficiency and transcription factor (MiT/TFE) fusions, producing oncometabolite accumulation (fumarate/succinate), dioxygenase inhibition (pseudohypoxia), CIMP hypermethylation, EMT, and vulnerabilities to PARP inhibition and arginine deprivation (coffey2024metabolicalterationsin pages 25-26, coffey2024metabolicalterationsin pages 8-9). Chromophobe RCC (chRCC) presents widespread chromosomal losses, mtDNA depletion, diminished ETC protein levels, and elevated glutathione, reflecting distinctive mitochondrial/redox states compared to oncocytoma and suggesting ferroptosis/redox-targeting opportunities (coffey2024metabolicalterationsin pages 11-13, zhang2025thepathogenesisand pages 9-9).

The RCC tumor microenvironment (TME) features exhausted CD8+ T cells, Tregs, M2‑like TAMs, aberrant vasculature, and metabolite gradients (lactate, hypoxia) that shape immune evasion. Spatial/single-cell profiling of bone metastases reveals MDSC→TAM trajectories, MRC1+FOLR2+ TAMs, and CD47+ T‑cell niches; these data illuminate pre‑metastatic/metastatic niche biology and therapeutic targets (coffey2024metabolicalterationsin pages 30-32). Collectively, genotype–epigenotype–metabolism–immunity couplings drive RCC initiation, progression, metastasis, and therapy response.

Category Entity (HGNC / Label) Primary mechanism / role (concise) Major subtype(s) Key pathway / process (GO term label) Subcellular location (GO-CC) Sources
Gene VHL E3 ligase for HIFα; tumor suppressor ccRCC response to hypoxia (GO:0001666) cytosol / nucleus (coffey2024metabolicalterationsin pages 30-32, nguyen2024novelapproacheswith pages 1-2)
Gene EPAS1 (HIF2A) Hypoxia transcription factor; drives angiogenesis, lipids ccRCC HIF signaling / angiogenesis nucleus (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32)
Gene HIF1A Hypoxia TF; induces glycolytic program ccRCC glycolytic process (GO:0006096) nucleus (coffey2024metabolicalterationsin pages 30-32, nguyen2024novelapproacheswith pages 1-2)
Gene PBRM1 SWI/SNF chromatin remodeler; tumor suppressor ccRCC chromatin organization (GO:0006325) nucleus / chromatin (coffey2024metabolicalterationsin pages 30-32)
Gene BAP1 Deubiquitinase; chromatin modifier, prognosis marker ccRCC chromatin modification (GO:0016570) nucleus (coffey2024metabolicalterationsin pages 30-32)
Gene SETD2 H3K36 methyltransferase; DNA repair/epigenetic regulator ccRCC histone methylation (GO:0018024) nucleus (coffey2024metabolicalterationsin pages 30-32)
Gene MET Receptor tyrosine kinase; growth and EMT driver pRCC (type 1) HGF/MET signaling (GO label) plasma membrane (coffey2024metabolicalterationsin pages 25-26)
Gene FH TCA enzyme; fumarate accumulation (oncometabolite) pRCC type 2 / HLRCC tricarboxylic acid cycle (GO:0006099) mitochondrion (coffey2024metabolicalterationsin pages 8-9)
Gene SDHB/SDHC/SDHD Complex II subunits; SDH-deficient oncometabolism SDH-deficient RCC electron transport chain / TCA mitochondrion (coffey2024metabolicalterationsin pages 8-9, coffey2024metabolicalterationsin pages 11-13)
Gene PTEN PI3K pathway suppressor; mTOR regulator chRCC, others PI3K-AKT signaling (GO:0008286) cytosol / membrane (coffey2024metabolicalterationsin pages 36-38, coffey2024metabolicalterationsin pages 30-32)
Gene PPARGC1A (PGC-1α) Mitochondrial biogenesis regulator; often suppressed ccRCC mitochondrial biogenesis (GO:0007005) nucleus / mitochondrial (zhang2025thepathogenesisand pages 9-9, bezwada2024mitochondrialcomplexi pages 1-2)
Gene GLS1 (GLS) Glutaminase; drives glutamine catabolism ccRCC glutamine metabolic process (GO label) mitochondrion (zhang2025thepathogenesisand pages 11-11, coffey2024metabolicalterationsin pages 19-21)
Gene LDHA Lactate dehydrogenase A; glycolysis effector ccRCC, pRCC glycolytic process (GO:0006096) cytosol (coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 25-26)
Gene SCARB1 HDL receptor; mediates cholesterol uptake, lipid storage ccRCC cholesterol transport (GO:0015918) plasma membrane (coffey2024metabolicalterationsin pages 36-38, coffey2024metabolicalterationsin pages 30-32)
Cell type Proximal tubule epithelial cell (CL) Renal epithelial origin of many RCCs ccRCC origin epithelial differentiation (GO:0030855) apical membrane / cytoplasm (coffey2024metabolicalterationsin pages 30-32)
Cell type Tumor-associated macrophage (CL) Immunosuppressive, pro-tumor M2-like activity all RCC TMEs regulation of immune response (GO:0050776) extracellular / TME (coffey2024metabolicalterationsin pages 36-38, zhang2025thepathogenesisand pages 11-11)
Cell type Regulatory T cell (Treg) (CL) Suppresses CD8+ antitumor responses; cancer-promoting subset ccRCC negative regulation immune response (GO:0002683) nucleus / cytosol (coffey2024metabolicalterationsin pages 36-38, zhang2025thepathogenesisand pages 11-11)
Cell type Endothelial cell (CL) Drives angiogenesis and pre-metastatic niche formation ccRCC angiogenesis (GO:0001525) plasma membrane (zhang2025thepathogenesisand pages 8-9, nguyen2024novelapproacheswith pages 1-2)
Anatomical site Kidney cortex (UBERON) Primary site; tubular epithelium origin primary RCC renal tubular processes (GO label) tissue compartment (coffey2024metabolicalterationsin pages 30-32)
Anatomical site Bone (UBERON) Frequent metastatic site; osteolytic niche metastatic RCC bone resorption (GO:0045121) bone tissue (bezwada2024mitochondrialcomplexi pages 1-2, zhang2025thepathogenesisand pages 8-9)
Chemical Glutamine (CHEBI) Metabolic fuel; supports glutaminolysis ccRCC metabolic dependency amino-acid metabolism (GO label) cytosol / mitochondrion (zhang2025thepathogenesisand pages 11-11, coffey2024metabolicalterationsin pages 19-21)
Chemical Lactate (CHEBI) Oncometabolite; acidifies TME, immunosuppressive ccRCC TME lactate metabolic process (GO:0019752) extracellular (coffey2024metabolicalterationsin pages 11-13, zhang2025thepathogenesisand pages 11-11)
Chemical Belzutifan (CHEBI) Small-molecule HIF-2α inhibitor; approved therapy VHL-associated & sporadic mRCC inhibition of HIF-2α activity (GO label) cytosol / nucleus target (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32)
Chemical Fumarate (CHEBI) Oncometabolite; inhibits αKG-dioxygenases (epigenetic) FH-deficient RCC prolyl hydroxylase inhibition / CIMP mitochondrion / cytosol (coffey2024metabolicalterationsin pages 8-9)

Table: Compact two-part table mapping key RCC genes/proteins to mechanisms, subtypes, GO processes and locations, plus cell types, anatomical sites, chemicals and disrupted processes — with source IDs for reference.; useful for ontology annotation and rapid mechanistic lookup.

1. Core Pathophysiology

  • Primary mechanisms: VHL loss → HIF stabilization (HIF‑2α>HIF‑1α) → angiogenesis (VEGF), glycolysis, lipid storage, c‑Myc/cell‑cycle programs; immune evasion via PD‑L1 and kynurenine pathway (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 36-38).
  • Dysregulated pathways: HIF signaling; PI3K/AKT/mTOR; MET/HGF in pRCC; TCA/ETC remodeling with context-dependent OXPHOS; amino-acid metabolism (glutamine, tryptophan); ferroptosis control (GPX4/glutathione) (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 8-9, bezwada2024mitochondrialcomplexi pages 1-2, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 30-32).
  • Affected cellular processes: chromatin remodeling and DNA repair (PBRM1, BAP1, SETD2); EMT and invasion; angiogenesis; metabolic plasticity; T‑cell exhaustion and myeloid reprogramming (coffey2024metabolicalterationsin pages 30-32, bezwada2024mitochondrialcomplexi pages 1-2, tian2024targetingoxidativephosphorylation pages 1-2).

Key quotes/data: - “ccRCC metastases unexpectedly have enhanced TCA cycle labelling… stimulating respiration or NADH recycling… promotes metastasis… inhibiting complex I decreases metastasis” (Nature, 14 Aug 2024, doi:10.1038/s41586-024-07812-3) (bezwada2024mitochondrialcomplexi pages 1-2). - “High OXPHOS levels are risk factors for ICI [failure]… shNdufb8 tumors had higher CD8+ T cells, less hypoxia, and improved responses to anti‑PD‑L1” (JITC, Feb 2024, doi:10.1136/jitc-2023-008226) (tian2024targetingoxidativephosphorylation pages 1-2).

2. Key Molecular Players

  • Genes/Proteins (HGNC): VHL, EPAS1(HIF2A), HIF1A, PBRM1, BAP1, SETD2, MET, FH, SDHB/SDHC/SDHD, PTEN, PPARGC1A(PGC‑1α), GLS, LDHA, SCARB1; see embedded table for roles and GO/CC context (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 8-9, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 36-38).
  • Chemical entities (CHEBI): belzutifan (HIF‑2α inhibitor), fumarate/succinate (oncometabolites), glutamine, lactate; functions in metabolism/therapy (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 8-9, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 36-38).
  • Cell types (CL): proximal tubule epithelium (cell of origin), TAMs (MRC1+FOLR2+), Tregs, exhausted CD8+ T cells (coffey2024metabolicalterationsin pages 30-32, tian2024targetingoxidativephosphorylation pages 1-2).
  • Anatomical locations (UBERON): kidney cortex (primary site), bone (common metastatic niche with osteolytic biology) (bezwada2024mitochondrialcomplexi pages 1-2, zhang2025thepathogenesisand pages 8-9).

3. Biological Processes (for GO annotation)

  • Response to hypoxia; HIF signaling; angiogenesis; glycolytic process; oxidative phosphorylation; glutamine metabolic process; tryptophan/kynurenine pathway; chromatin organization; histone methylation; EMT; regulation of immune response; ferroptosis regulation (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32, tian2024targetingoxidativephosphorylation pages 1-2, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 8-9).

4. Cellular Components

  • Nucleus (HIF transcriptional effects; chromatin remodelers PBRM1/BAP1/SETD2). Mitochondrion (TCA/ETC, GLS1, OXPHOS, mtDNA depletion in chRCC). Plasma membrane (MET, SCARB1; PD‑L1). Extracellular space (lactate, IDO/kynurenine signaling) (coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 8-9, tian2024targetingoxidativephosphorylation pages 1-2).

5. Disease Progression

  • Initiation: 3p loss (VHL±PBRM1/BAP1/SETD2) in ccRCC; MET activation in pRCC; FH/SDH loss in hereditary/Type 2 pRCC (coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 8-9, coffey2024metabolicalterationsin pages 25-26).
  • Early growth: HIF‑2α–driven angiogenesis and metabolic rewiring (glycolysis, lipid storage; glutamine use); immune modulation (PD‑L1, IDO) (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 36-38).
  • Progression/metastasis: EMT/inflammation subclones, chromatin remodeling divergence; metastases adopt higher TCA/ETC flux; pre‑metastatic niche priming and organotropism (bone) with myeloid and endothelial remodeling (coffey2024metabolicalterationsin pages 30-32, bezwada2024mitochondrialcomplexi pages 1-2).

6. Phenotypic Manifestations (HP terms)

  • Hypervascular renal mass, paraneoplastic cachexia/hypercalcemia (HIF‑related), anemia, immune cold/excluded phenotypes, osteolytic bone lesions in metastasis, variable responses to ICIs dependent on OXPHOS/TME state (nguyen2024novelapproacheswith pages 1-2, tian2024targetingoxidativephosphorylation pages 1-2, bezwada2024mitochondrialcomplexi pages 1-2).

Recent Developments and Latest Research (2023–2024 prioritized)

  • Nature 2024: Primary ccRCC has suppressed TCA/ETC; metastases increase TCA flux; complex I inhibition curtails metastasis—shifting views on mitochondrial targeting in advanced RCC (Aug 14, 2024; https://doi.org/10.1038/s41586-024-07812-3) (bezwada2024mitochondrialcomplexi pages 1-2).
  • JITC 2024: High OXPHOS programs predict ICI resistance; targeting complex I alleviates hypoxia and reinvigorates CD8+ T cells, suggesting combinatorial strategies (Feb 2024; https://doi.org/10.1136/jitc-2023-008226) (tian2024targetingoxidativephosphorylation pages 1-2).
  • Nat Rev Nephrol 2024: Integrative review codifies RCC as a metabolic disease across subtypes; details MET/pRCC, FH/SDH oncometabolism, ferroptosis liabilities, tryptophan metabolism–immune links (Jan 2024; https://doi.org/10.1038/s41581-023-00800-2) (coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 19-21, coffey2024metabolicalterationsin pages 25-26, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 36-38).

Current Applications and Real‑World Implementations

  • Targeted therapy: HIF‑2α inhibitor belzutifan approved for VHL‑associated and sporadic mRCC; mechanistic basis in VHL/HIF biology (Jan 31, 2024; https://doi.org/10.3390/cancers16030601) (nguyen2024novelapproacheswith pages 1-2).
  • Therapeutic strategy design: OXPHOS/complex I inhibition combined with PD‑(L)1 to overcome hypoxia‑driven T cell dysfunction (tian2024targetingoxidativephosphorylation pages 1-2). VEGF pathway inhibition guided by angiogenic HIF programs; MET inhibitors in pRCC type 1 (coffey2024metabolicalterationsin pages 25-26, nguyen2024novelapproacheswith pages 1-2).

Expert Opinions and Authoritative Analyses

  • Coffey & Simon 2024 (Nature Reviews Nephrology) synthesize hereditary/sporadic RCC metabolic mechanisms, highlighting shared vulnerabilities and the need for subtype‑specific modeling (Jan 2024; https://doi.org/10.1038/s41581-023-00800-2) (coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 19-21, coffey2024metabolicalterationsin pages 25-26, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 36-38).

Relevant Statistics and Data

  • 80 patients: intraoperative 13C infusions demonstrate suppressed TCA labeling in primary ccRCC vs adjacent kidney; higher TCA labeling in metastases; complex I inhibition decreases metastasis in mice (Nature, 2024) (bezwada2024mitochondrialcomplexi pages 1-2).

  • High OXPHOS signature associates with poorer ICI responses across CheckMate/JAVELIN datasets; shNdufb8 tumors show increased CD8+ T cell infiltration and function under anti‑PD‑L1 therapy (JITC, 2024) (tian2024targetingoxidativephosphorylation pages 1-2).

Gene/Protein Annotations with Ontology Terms

  • VHL (HGNC:12687): GO:0001666 response to hypoxia; GO:0006511 ubiquitin-dependent protein catabolic process; nucleus/cytosol (nguyen2024novelapproacheswith pages 1-2, coffey2024metabolicalterationsin pages 30-32).
  • EPAS1/HIF2A (HGNC:3373): GO:0001525 angiogenesis; GO:0006355 regulation of transcription; nucleus (nguyen2024novelapproacheswith pages 1-2).
  • PBRM1 (HGNC:30022): GO:0006338 chromatin remodeling; nucleus/chromatin (coffey2024metabolicalterationsin pages 30-32).
  • BAP1 (HGNC:949): GO:0016570 histone deubiquitination; nucleus (coffey2024metabolicalterationsin pages 30-32).
  • SETD2 (HGNC:15920): GO:0018024 histone lysine methylation (H3K36me3); nucleus (coffey2024metabolicalterationsin pages 30-32).
  • MET (HGNC:7029): GO:0007167 enzyme linked receptor protein signaling; plasma membrane (coffey2024metabolicalterationsin pages 25-26).
  • FH (HGNC:3700): GO:0006108 malate metabolic process; mitochondrion (coffey2024metabolicalterationsin pages 8-9).

Phenotype Associations (HP terms)

  • HP:0009725 Renal cell carcinoma; HP:0002664 Anemia; HP:0003002 Cachexia; HP:0031286 Hypercalcemia; HP:0100244 Osteolytic bone lesions; HP:0031351 Immunodeficiency due to T‑cell dysfunction (nguyen2024novelapproacheswith pages 1-2, bezwada2024mitochondrialcomplexi pages 1-2, tian2024targetingoxidativephosphorylation pages 1-2).

Cell Type Involvement (CL terms)

  • CL:0002328 Proximal tubule epithelial cell (cell of origin in many RCCs). CL:0000738 Regulatory T cell. CL:0000235 Macrophage (MRC1+FOLR2+ TAMs). CL:0000625 Endothelial cell (coffey2024metabolicalterationsin pages 30-32, tian2024targetingoxidativephosphorylation pages 1-2).

Anatomical Locations (UBERON terms)

  • UBERON:0001225 Kidney cortex (primary). UBERON:0001474 Bone (metastatic niche) (bezwada2024mitochondrialcomplexi pages 1-2).

Chemical Entities (CHEBI)

  • CHEBI:19508 Fumarate (oncometabolite in FH‑deficiency). CHEBI:30744 Glutamine (metabolic fuel). CHEBI:16651 L‑lactate (TME metabolite). Belzutifan (HIF‑2α inhibitor; drug entity) (coffey2024metabolicalterationsin pages 8-9, coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 30-32, nguyen2024novelapproacheswith pages 1-2).

Evidence Items (with URLs and dates)

  • Bezwada et al., Nature, 14 Aug 2024. “Mitochondrial complex I promotes kidney cancer metastasis.” https://doi.org/10.1038/s41586-024-07812-3 (bezwada2024mitochondrialcomplexi pages 1-2).
  • Tian et al., J Immunother Cancer, Feb 2024. “Targeting oxidative phosphorylation to increase the efficacy of immune‑combination therapy in RCC.” https://doi.org/10.1136/jitc-2023-008226 (tian2024targetingoxidativephosphorylation pages 1-2).
  • Coffey & Simon, Nat Rev Nephrol, Jan 2024. “Metabolic alterations in hereditary and sporadic RCC.” https://doi.org/10.1038/s41581-023-00800-2 (coffey2024metabolicalterationsin pages 11-13, coffey2024metabolicalterationsin pages 19-21, coffey2024metabolicalterationsin pages 25-26, coffey2024metabolicalterationsin pages 30-32, coffey2024metabolicalterationsin pages 36-38).
  • Nguyen et al., Cancers, 31 Jan 2024. “Novel approaches with HIF‑2α targeted therapies in mRCC.” https://doi.org/10.3390/cancers16030601 (nguyen2024novelapproacheswith pages 1-2).
  • Wu et al., Nature Communications, 20 Mar 2023. “Epigenetic and transcriptomic characterization…ccRCC.” https://doi.org/10.1038/s41467-023-37211-7 (coffey2024metabolicalterationsin pages 30-32).

Expert Synthesis and Implications

  • Mechanistic integration indicates: (i) VHL/HIF‑2α is foundational in ccRCC, (ii) chromatin remodelers modulate EMT/inflammation programs and TME engagement, (iii) metabolic states are stage‑dependent (primary vs metastatic), with therapeutic windows differing across disease phases, and (iv) immunometabolic features (OXPHOS/hypoxia, tryptophan metabolism) condition ICI responses. These insights argue for phase‑adapted metabolic targeting (e.g., complex I inhibition in metastatic settings) and rational ICI combinations guided by OXPHOS hypoxia signatures and spatial immune readouts (bezwada2024mitochondrialcomplexi pages 1-2, tian2024targetingoxidativephosphorylation pages 1-2, coffey2024metabolicalterationsin pages 36-38).

References

  1. (nguyen2024novelapproacheswith pages 1-2): Charles B. Nguyen, Eugene Oh, Piroz Bahar, Ulka N. Vaishampayan, Tobias Else, and Ajjai S. Alva. Novel approaches with hif-2α targeted therapies in metastatic renal cell carcinoma. Cancers, 16:601, Jan 2024. URL: https://doi.org/10.3390/cancers16030601, doi:10.3390/cancers16030601. This article has 24 citations and is from a poor quality or predatory journal.

  2. (coffey2024metabolicalterationsin pages 30-32): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  3. (bezwada2024mitochondrialcomplexi pages 1-2): Divya Bezwada, Luigi Perelli, Nicholas P. Lesner, Ling Cai, Bailey Brooks, Zheng Wu, Hieu S. Vu, Varun Sondhi, Daniel L. Cassidy, Stacy Kasitinon, Sherwin Kelekar, Feng Cai, Arin B. Aurora, McKenzie Patrick, Ashley Leach, Rashed Ghandour, Yuanyuan Zhang, Duyen Do, Phyllis McDaniel, Jessica Sudderth, Dennis Dumesnil, Sara House, Tracy Rosales, Alan M. Poole, Yair Lotan, Solomon Woldu, Aditya Bagrodia, Xiaosong Meng, Jeffrey A. Cadeddu, Prashant Mishra, Javier Garcia-Bermudez, Ivan Pedrosa, Payal Kapur, Kevin D. Courtney, Craig R. Malloy, Giannicola Genovese, Vitaly Margulis, and Ralph J. DeBerardinis. Mitochondrial complex i promotes kidney cancer metastasis. Nature, 633:923-931, Aug 2024. URL: https://doi.org/10.1038/s41586-024-07812-3, doi:10.1038/s41586-024-07812-3. This article has 86 citations and is from a highest quality peer-reviewed journal.

  4. (tian2024targetingoxidativephosphorylation pages 1-2): Jihua Tian, Jing Luo, Xing Zeng, Chunjin Ke, Yanan Wang, Zhenghao Liu, Le Li, Yangjun Zhang, Zhiquan Hu, and Chunguang Yang. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma. Journal for Immunotherapy of Cancer, 12:e008226, Feb 2024. URL: https://doi.org/10.1136/jitc-2023-008226, doi:10.1136/jitc-2023-008226. This article has 19 citations and is from a domain leading peer-reviewed journal.

  5. (coffey2024metabolicalterationsin pages 11-13): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  6. (coffey2024metabolicalterationsin pages 19-21): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  7. (coffey2024metabolicalterationsin pages 36-38): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  8. (coffey2024metabolicalterationsin pages 25-26): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  9. (coffey2024metabolicalterationsin pages 8-9): Nathan J. Coffey and M. Celeste Simon. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature reviews. Nephrology, 20:233-250, Jan 2024. URL: https://doi.org/10.1038/s41581-023-00800-2, doi:10.1038/s41581-023-00800-2. This article has 36 citations.

  10. (zhang2025thepathogenesisand pages 9-9): Yifan Zhang, Shengli Zhang, Hongbin Sun, and Luwei Xu. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discovery, Apr 2025. URL: https://doi.org/10.1038/s41420-025-02479-9, doi:10.1038/s41420-025-02479-9. This article has 27 citations and is from a peer-reviewed journal.

  11. (zhang2025thepathogenesisand pages 11-11): Yifan Zhang, Shengli Zhang, Hongbin Sun, and Luwei Xu. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discovery, Apr 2025. URL: https://doi.org/10.1038/s41420-025-02479-9, doi:10.1038/s41420-025-02479-9. This article has 27 citations and is from a peer-reviewed journal.

  12. (zhang2025thepathogenesisand pages 8-9): Yifan Zhang, Shengli Zhang, Hongbin Sun, and Luwei Xu. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discovery, Apr 2025. URL: https://doi.org/10.1038/s41420-025-02479-9, doi:10.1038/s41420-025-02479-9. This article has 27 citations and is from a peer-reviewed journal.

OpenAI ▸
Renal Cell Carcinoma Pathophysiology
o3-deep-research-2025-06-26 165 citations 2026-02-01T10:05:08.856842

Renal Cell Carcinoma Pathophysiology

Renal cell carcinoma (RCC) is a malignant tumor arising from the epithelial cells of the renal tubules in the kidney (primarily the renal cortex, UBERON:0002314) (pmc.ncbi.nlm.nih.gov). It is a heterogeneous disease at both the genomic and cellular level, but clear cell renal cell carcinoma (ccRCC) is the most common subtype, accounting for ~75–80% of cases (pmc.ncbi.nlm.nih.gov). The pathophysiology of RCC is driven by multi-step molecular alterations that dysregulate key cellular pathways, leading to uncontrolled cell growth, angiogenesis, metabolic reprogramming, and immune evasion. Below, we detail the core mechanisms of RCC progression, highlighting the genes (HGNC symbols), molecular pathways (GO processes), cellular components, and resultant clinical phenotypes (HP terms), with evidence from recent research and expert analyses.

Core Pathophysiological Mechanisms

1. Hypoxia Signaling and Angiogenesis: The most prominent pathway in ccRCC is the dysregulation of cellular oxygen-sensing. In normal cells, the von Hippel–Lindau (VHL) tumor suppressor gene (HGNC:12687) encodes an E3 ubiquitin ligase component (pVHL) that targets hypoxia-inducible factor alpha (HIF-α) for degradation in the presence of oxygen (pmc.ncbi.nlm.nih.gov). Loss of VHL function (through mutation or chromosomal deletion on 3p) is a near-universal initiating event in ccRCC (present in up to 90% of tumors) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In VHL-proficient cells under normoxia, HIF-α subunits (HIF1α and HIF2α) are proline-hydroxylated and bind pVHL, leading to their ubiquitination and proteasomal destruction (pmc.ncbi.nlm.nih.gov). VHL inactivation (biallelic loss) abrogates this process – mimicking a constant hypoxic state or “pseudohypoxia.” Stabilized HIF-α translocates to the nucleus (GO:0005634) and dimerizes with HIF-1β (ARNT), functioning as a transcription factor that massively upregulates hypoxia-responsive genes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As a result, RCC cells overproduce pro-angiogenic and growth factors like vascular endothelial growth factor A (VEGFA), platelet-derived growth factor-B (PDGFB), and transforming growth factor-α (TGF-α) (pmc.ncbi.nlm.nih.gov). These HIF target genes drive angiogenesis (GO:0001525) and tumor vascularization, a hallmark of ccRCC which often appears as highly vascular masses prone to hemorrhage (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). HIF also induces GLUT1 and other glycolysis enzymes to shift metabolism toward glycolysis, and stimulates erythropoietin (EPO) production, explaining why some RCC patients develop polycythemia (high red blood cell count) due to ectopic EPO secretion (pmc.ncbi.nlm.nih.gov). In summary, the VHL/HIF pathway dysregulation is a core driver of RCC, often termed the “engine” of ccRCC pathogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This mechanism was first elucidated by Dr. William Kaelin and colleagues (Nobel Prize 2019) (pmc.ncbi.nlm.nih.gov) and remains a central therapeutic target in RCC. A 2024 JAMA review emphasizes that these molecular insights have enabled therapies targeting the underlying hypoxia–angiogenesis pathophysiology (pmc.ncbi.nlm.nih.gov).

2. Tumor Suppressor Loss and Chromatin Remodeling: In addition to VHL, several other tumor suppressor genes on chromosome 3p and elsewhere are frequently inactivated in RCC, contributing to tumor progression. Notably, PBRM1 (HGNC:16289, encoding BAF180) is mutated in ~41% of ccRCCs (pmc.ncbi.nlm.nih.gov). PBRM1 is part of the SWI/SNF chromatin-remodeling complex (the PBAF complex) and helps regulate gene expression by modifying nucleosome positioning (pmc.ncbi.nlm.nih.gov). Loss of PBRM1 impairs normal chromatin dynamics, leading to uncontrolled cell-cycle progression (failure of cell cycle arrest) and increased proliferation (pmc.ncbi.nlm.nih.gov). Similarly, BAP1 (HGNC:18586, BRCA1-associated protein 1) is mutated in ~10–15% of ccRCC (pmc.ncbi.nlm.nih.gov). BAP1 encodes a nuclear deubiquitinase involved in histone modification and chromatin regulation; its loss is associated with more aggressive, high-grade tumors and poorer prognosis (pmc.ncbi.nlm.nih.gov). Mechanistically, wild-type BAP1 forms complexes (e.g. with HCF1) that suppress cell proliferation, and BAP1 loss removes these brakes on growth (pmc.ncbi.nlm.nih.gov). Another key gene is SETD2 (HGNC:17076), mutated in ~10–15% of ccRCC (pmc.ncbi.nlm.nih.gov). SETD2 is the sole methyltransferase for histone H3 lysine 36 trimethylation (H3K36me3) and is critical for DNA damage repair and RNA splicing fidelity. SETD2 loss leads to genomic instability and altered chromatin structure. KDM5C (HGNC:6293), a histone demethylase, and TP53 (HGNC:11998) or PTEN (HGNC:9588) are also occasionally mutated, further disrupting cell cycle control and signaling (pmc.ncbi.nlm.nih.gov). Collectively, these tumor suppressor losses result in defective chromatin organization (GO:0006325), epigenetic dysregulation (GO:0045814) of gene expression, and loss of genome integrity, which cooperate with the VHL/HIF pathway to drive RCC progression. Notably, chromosome 3p deletions often encompass multiple such genes (VHL, PBRM1, BAP1, SETD2), explaining why a single early 3p loss event can knock out several tumor suppressors at once (pmc.ncbi.nlm.nih.gov). The TCGA comprehensive molecular characterization (2013) showed 95% of ccRCCs have 3p loss and recurrent mutations in these genes (pmc.ncbi.nlm.nih.gov). Researchers have proposed an evolutionary model where VHL loss is the truncal (first) event, and subsequent divergence into indolent vs. aggressive subclones is partly driven by whether PBRM1 or BAP1 is lost next – BAP1 mutations tending to confer higher grade and metastatic potential (pmc.ncbi.nlm.nih.gov). This sequential mutational path underlies distinct clinical trajectories within ccRCC (with PBRM1-mutant tumors often less aggressive than BAP1-mutant tumors, consistent with their prognoses (pmc.ncbi.nlm.nih.gov)).

3. Oncogenic Signaling Pathways (PI3K/AKT/mTOR and MET): RCC cells frequently harbor alterations in growth factor signaling pathways that promote cell survival, proliferation, and metabolism. The PI3K–AKT–mTOR pathway is commonly activated in RCC, either via mutations or downstream effects of the HIF pathway. The mTOR kinase (from the MTOR gene, HGNC:3942) is a central regulator of cell growth and metabolism. In RCC, gain-of-function mutations in MTOR and in components like PIK3CA (PI3K catalytic subunit) or loss of the PTEN tumor suppressor (a PI3K pathway inhibitor) have been reported (pmc.ncbi.nlm.nih.gov). Even in the absence of mutation, HIF overexpression can stimulate mTOR activity: HIF upregulates growth factors (like PDGF and TGF-α) that activate receptor tyrosine kinases, in turn activating PI3K/AKT signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Active mTOR forms two complexes (mTORC1/2) that phosphorylate effectors such as p70S6 kinase and 4E-BP1, enhancing protein synthesis and angiogenesis (e.g. increasing VEGF and TGF-β production) (pmc.ncbi.nlm.nih.gov). Net effects include robust cell proliferation (GO:0008283), growth, and inhibition of apoptosis. Indeed, mTOR signaling is hyperactive in many RCCs, and mTOR inhibitors (rapalog drugs like temsirolimus and everolimus, CHEBI:Temsirolimus) have shown clinical efficacy in metastatic RCC (pmc.ncbi.nlm.nih.gov). Another critical pathway is the MET proto-oncogene (HGNC:7029), which encodes the hepatocyte growth factor receptor (HGFR). MET is especially relevant in papillary RCC (pRCC), the second most common subtype (~15% of RCC). Type 1 pRCC often features activating mutations of MET or chromosomal gains of 7q (harboring MET), driving oncogenic MET signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This leads to constant stimulation of the RAS–MAPK and PI3K–AKT cascades, promoting tumor cell proliferation and survival. Type 2 pRCC, in contrast, is frequently driven by alterations in genes like CDKN2A, NF2, or metabolic genes (FH, SDHB; see below) and tends to be more aggressive (pmc.ncbi.nlm.nih.gov). In both clear cell and non-clear cell RCC variants, dysregulated kinase signaling is a theme. For example, in some chromophobe RCC (a distinct subtype arising from distal tubules), mutations in TSC1/TSC2 or the tumor suppressor FLCN (Folliculin, mutated in Birt–Hogg–Dubé syndrome) lead to mTOR pathway activation and abnormal metabolic signaling (pmc.ncbi.nlm.nih.gov). Overall, constitutive activation of pro-growth signaling pathways (via oncogenes or loss of negative regulators) is a key mechanism by which RCC cells attain autonomy from normal growth controls.

4. Metabolic Reprogramming (“Warburg Effect” and Oncometabolites): RCC, particularly ccRCC, has pronounced metabolic alterations. The clear-cell morphology is due to intracellular accumulation of lipids and glycogen, reflecting metabolic reprogramming. HIF-1 activation encourages a shift from oxidative phosphorylation in mitochondria to aerobic glycolysis (GO:0006096), even in oxygen-replete conditions (the Warburg effect) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This provides rapidly dividing tumor cells with metabolic intermediates for biosynthesis. ccRCC tumors upregulate GLUT1 glucose transporters and glycolytic enzymes via HIF, increasing glucose uptake and lactate production (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They also rely on glutamine metabolism: glutamine is converted to glutamate by glutaminase (GLS1), feeding the TCA cycle and providing carbon for nucleotide (pyrimidine) synthesis (pmc.ncbi.nlm.nih.gov). In fact, VHL-deficient RCC cells exhibit glutamine addiction, using glutamine anaplerosis to support growth, and this is being targeted in trials (e.g. GLS inhibitor CB-839 in RCC) (pmc.ncbi.nlm.nih.gov). Moreover, certain hereditary RCC syndromes illustrate how metabolic enzyme defects drive tumorigenesis via oncometabolites. For instance, fumarate hydratase (FH) mutation in Hereditary Leiomyomatosis and RCC (HLRCC) leads to fumarate accumulation. Excess fumarate (CHEBI:18012) and succinate can inhibit prolyl hydroxylase enzymes (which require α-ketoglutarate as cofactor) that normally hydroxylate HIF (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, FH-deficient tumors also exhibit pseudohypoxia with HIF stabilization, much like VHL loss. Accumulated fumarate and succinate can cause epigenetic changes and generate reactive oxygen species (ROS), further stabilizing HIF-α and activating the NRF2 antioxidant response pathway (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These metabolic derangements (captured by GO terms like cellular metabolic process, GO:0044237) are not mere bystanders; they are central to RCC biology. A 2019 study showed that FH-deficient kidney cancer cells become highly dependent on glycolysis and ROS signaling to drive HIF activation (pmc.ncbi.nlm.nih.gov). Similarly, loss of succinate dehydrogenase (SDH) in rare RCC subsets causes succinate accumulation and HIF/NRF2 pathway upregulation (“pseudohypoxia” and oxidative stress) (pmc.ncbi.nlm.nih.gov). The net effect is that RCC cells rewire metabolism to favor growth: increasing glucose and glutamine utilization, suppressing mitochondrial respiration, accumulating lipids (explaining the clear cell phenotype), and thriving in low nutrient and oxygen conditions. These metabolic vulnerabilities are being explored for therapy (e.g. HIF-2α inhibitors, glutaminase inhibitors, and metabolic enzyme targets).

5. Immune Evasion and Microenvironment: RCC has long been recognized as an “immunogenic” tumor – paradoxically, it often triggers immune cell infiltration yet manages to evade immune destruction. The tumor microenvironment of RCC typically contains T lymphocytes (CL:0000084), including CD8+ cytotoxic T cells, as well as macrophages and other immune cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). One mechanism of immune evasion is the upregulation of immune checkpoint molecules. RCC cells commonly express PD-L1 (programmed death-ligand 1) on their surface, which binds PD-1 receptors on T cells and inhibits T cell activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This PD-1/PD-L1 pathway (GO:0072626) effectively turns off the anti-tumor immune response, allowing tumor escape. Indeed, immune checkpoint inhibitor therapy (antibodies against PD-1 or PD-L1, and CTLA-4) can unleash an immune attack on RCC and has led to durable remissions in a subset of patients (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The presence of tumor-infiltrating lymphocytes is an important feature; in fact, a 2016 genomic study found that ccRCC tumors have distinct mRNA signatures reflecting the immune microenvironment, correlating with prognosis and response to immunotherapy (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Other immune evasion tactics include loss of MHC I expression and secretion of immunosuppressive cytokines. Furthermore, the tumor stroma (fibroblasts, endothelium) in RCC contributes to tumor growth – for example, carcinoma-associated fibroblasts secrete growth factors that create a pro-proliferative niche at the tumor periphery (pmc.ncbi.nlm.nih.gov). The robust vascular network in RCC also means immune cells often have access to the tumor, but the tumor can create an immunosuppressive milieu to prevent effective clearance. This dynamic between RCC and the immune system underlies why high-dose IL-2 immunotherapy showed occasional complete responses historically, and why modern checkpoint inhibitors are now standard in advanced RCC. In summary, RCC pathophysiology includes an immune component: the cancer’s ability to dampen cytotoxic T-cell responses (GO:0034097) is critical for its survival, and reversing this immunosuppression has become a therapeutic cornerstone.

Key Molecular Players and Dysregulated Pathways

RCC involves a multitude of molecular players across different biological processes. Below is a summary of the key genes/proteins, cellular contexts, and biochemical factors that drive RCC pathogenesis, along with their roles:

  • Von Hippel–Lindau (VHL) – Tumor suppressor gene (3p25). Role: Oxygen sensor via degrading HIF-α under normoxia. Pathology: Inactivated in most ccRCC, causing HIF accumulation and activation of hypoxia response genes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Ontology: located in the cytosol (GO:0005829) as part of the VBC ubiquitin ligase complex (with Elongins B/C, CUL2) (pmc.ncbi.nlm.nih.gov). Loss leads to constitutive angiogenesis and cell proliferation (via VEGF, PDGF, etc.). Evidence: VHL mutations are found in ~50–60% of sporadic ccRCC by conventional sequencing and up to 90% when including epigenetic silencing (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Restoring VHL in VHL-deficient RCC cells curbs their growth, underscoring its causal role (pmc.ncbi.nlm.nih.gov).

  • Hypoxia-Inducible Factors (HIF1α, HIF2α) – Transcription factors stabilized by VHL loss or low oxygen. Role: Master regulators of hypoxic response; induce genes for angiogenesis, metabolic shift, and invasion. HIF2α (EPAS1, HGNC:3378) is particularly oncogenic in RCC, driving VEGF, EPO and survival pathways (pmc.ncbi.nlm.nih.gov). Cellular location: when active, HIFα/β dimer translocates to the nucleus to activate target genes (e.g. VEGFA (HGNC:12680), PGF, EPO). Evidence: HIF targets like carbonic anhydrase IX (CA9) and VEGF are highly expressed in ccRCC, and HIF2α-specific inhibitors have shown tumor regressions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In fact, belzutifan, a small-molecule HIF-2α inhibitor, was approved in 2021 for VHL syndrome RCC and in 2023 for refractory metastatic RCC (pubmed.ncbi.nlm.nih.gov) (www.merck.com), validating HIF2 as a therapeutic target. (Expert opinion: Dr. Toni Choueiri noted this HIF2 inhibitor provides a “meaningful new treatment option” for patients who progressed on immunotherapy and anti-VEGF therapy (www.merck.com).)*

  • PBRM1 (BAF180) – Chromatin remodeling complex subunit (3p21). Role: Part of PBAF SWI/SNF complex (GO:0016514) that regulates transcription by altering nucleosome positioning. Pathology: Second most common mutation in ccRCC (~40%). Loss of PBRM1 disrupts chromatin regulation, leading to abnormal gene expression and cell cycle progression (pmc.ncbi.nlm.nih.gov). Evidence: PBRM1-mutant RCC cells show impaired nucleosome sliding activity and are more proliferative; mutations co-occur with VHL loss and may influence tumor grade (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Importantly, PBRM1 status has been linked to immune response; some studies suggest PBRM1-deficient tumors might respond differently to immunotherapy, although this is under investigation.

  • BAP1 – Deubiquitinase enzyme (3p21). Role: Regulates histone ubiquitination and chromatin dynamics; interacts with HCF1 to control gene expression related to cell growth. Pathology: Mutated in ~10–15% of ccRCC, often exclusive of PBRM1 mutations (pmc.ncbi.nlm.nih.gov). BAP1-mutant tumors are typically high grade, with sarcomatoid or rhabdoid features more frequently, and portend worse survival (pmc.ncbi.nlm.nih.gov). Evidence: Germline BAP1 mutations cause a cancer syndrome with RCC, and somatic BAP1 loss in RCC is associated with increased metastasis (pmc.ncbi.nlm.nih.gov). Functionally, loss of BAP1 leads to uncontrolled cell proliferation due to failure to deubiquitinate H2A and other targets, disrupting normal growth arrest signals (pmc.ncbi.nlm.nih.gov).

  • SETD2 – Histone methyltransferase (3p21). Role: Tri-methylates H3K36 during DNA replication, important for DNA repair and transcript elongation. Pathology: Mutated in ~10% of ccRCC (and additional pRCC type2). Loss of SETD2 causes reduced H3K36me3 marks, impaired mismatch repair, and faulty DNA double-strand break repair. Evidence: SETD2 mutant RCCs have a high mutation rate and frequent chromosomal aberrations, highlighting the role of SETD2 in genomic stability. Immunohistochemistry for H3K36me3 can indicate SETD2 functional loss (low in mutant tumors) (pmc.ncbi.nlm.nih.gov). However, interestingly, one 2025 study found that SETD2 mutation didn’t always correlate with H3K36me3 levels regionally in a tumor, suggesting intratumoral heterogeneity in epigenetic effects (pmc.ncbi.nlm.nih.gov).

  • MTOR and PTEN – Kinase and lipid phosphatase in PI3K/AKT pathway. Role: mTOR promotes anabolic metabolism and cell growth; PTEN negatively regulates PI3K signaling. Pathology: Mutations activating mTOR (or PI3K) or inactivating PTEN occur in a subset of RCCs, especially some non-clear cell types and advanced cases (pmc.ncbi.nlm.nih.gov). Even without mutations, RCC often exhibits mTOR activation due to convergent signaling (from HIF, MET, etc.). Evidence: Clinicogenomic studies have attempted to correlate mTOR pathway mutations with response to mTOR inhibitor therapy; while some responding patients have mutations, many do not, indicating that mTOR activation can be driven by upstream signals in the absence of a direct mutation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Regardless, the mTOR pathway is a proven therapeutic target in RCC (e.g., temsirolimus improved survival in poor-risk metastatic RCC in a pivotal trial, leading to its approval).

  • MET and HGFR – Receptor tyrosine kinase (7q31). Role: Controls cell growth, invasion, and morphogenesis in response to hepatocyte growth factor (HGF). Pathology: Highly relevant in papillary RCC. Hereditary pRCC (Type 1) is often caused by germline MET mutations, and sporadic pRCC frequently shows MET activation (mutations or chromosome 7 gains) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). MET activation triggers the RAS/ERK and PI3K pathways, overlapping with other RCC growth signals. Evidence: Therapeutic targeting of MET in pRCC has shown efficacy: for example, the MET inhibitor savolitinib demonstrated tumor responses in MET-driven pRCC, and combination of MET/VEGFR inhibitor cabozantinib is effective in non-ccRCC. These underscore MET as a bona fide oncogenic driver in those tumors. Type 2 pRCC lacks MET mutations but often has metabolic gene mutations (e.g. FH) and co-mutations in chromatin genes (similar to ccRCC), reflecting different biology (pmc.ncbi.nlm.nih.gov).

  • FH (Fumarate Hydratase) and SDH (Succinate Dehydrogenase) – TCA cycle enzymes. Role: Mitochondrial enzymes; loss leads to oncometabolite buildup. Pathology: Biallelic loss of FH causes the HLRCC subtype of pRCC (aggressive type 2 pRCC); loss of SDH (SDHB/C/D subunits) causes a rare RCC variant often associated with paraganglioma syndromes (pmc.ncbi.nlm.nih.gov). Effect: Both result in accumulation of fumarate or succinate, which inhibit HIF prolyl hydroxylases and activate pseudohypoxia pathways (stabilizing HIF) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, fumarate can modify cysteine residues on proteins (succination), inactivating KEAP1 and leading to NRF2 pathway activation (an antioxidant transcription factor). The NRF2 pathway (NFE2L2/KEAP1 mutations or oncometabolite action) is another tumor-promoting mechanism in these cancers (pmc.ncbi.nlm.nih.gov). Evidence: Patients with germline FH mutations develop aggressive RCC early, indicating a strong oncogenic effect. Molecular studies show FH-deficient RCCs depend on glycolysis/GLUT1 (hence, “glycolytic addiction”) and generate high ROS which in turn stabilize HIF-1α (pmc.ncbi.nlm.nih.gov). These tumors also demonstrate a cachexia-like metabolic profile, consuming glucose and glutamine avidly. Therapeutically, they are refractory to standard VEGF inhibitors, but research is ongoing into targeting metabolic vulnerabilities (e.g. HIF2 inhibitors might be less effective if HIF1 is dominant; direct metabolic enzyme therapies are explored).

  • VEGF, PDGF, TGF-α, EGFR, IL-6, etc. – Soluble factors and receptors. These are not mutated drivers, but they are key chemical mediators in RCC’s pathology (many qualify as chemical entities, CHEBI). VEGF-A is the flagship pro-angiogenic factor induced by HIF; it diffuses in the extracellular space (GO:0005576) and signals via endothelial VEGF receptors to spur new blood vessel formation. PDGF-BB (platelet-derived growth factor) and TGF-α are also secreted by RCC cells under HIF/mTOR influence, acting in a paracrine fashion on stromal cells and endothelium to support angiogenesis and tumor stroma formation (pmc.ncbi.nlm.nih.gov). These factors cause the highly vascular tumor stroma characteristic of RCC. Clinically, this led to development of VEGF pathway inhibitors (like sunitinib, pazopanib, axitinib, and anti-VEGF antibody bevacizumab). Such drugs aim to starve the tumor by blocking angiogenesis, and they have significantly improved outcomes in metastatic RCC (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Other factors: IL-6 and IL-8 from tumor or immune cells can create an inflammatory milieu and are associated with paraneoplastic symptoms (fever, cachexia). PTHrP can be secreted by some RCC causing paraneoplastic hypercalcemia. Renin from juxtaglomerular cell involvement or tumor pressure can contribute to hypertension in some patients. Lastly, tumor expression of PD-L1 (a membrane protein) is a key “molecular player” of immune escape as described above, and therapies targeting PD-1/PD-L1 have reshaped RCC management.

Summary of dysregulated pathways: In GO terminology, RCC is marked by aberrant activation of processes like cellular response to hypoxia (GO:0071456), angiogenesis (GO:0001525), blood vessel development, positive regulation of cell proliferation (GO:0008284), suppression of apoptotic process, chromatin remodeling (GO:0006338), histone modification, gluconeogenesis/glycolysis balance, glutamine metabolic process, and immune response modulation. The convergence of genetic mutations (VHL, PBRM1, etc.) and microenvironment interactions leads to self-sustaining feedback loops: e.g., HIF-driven VEGF recruits blood vessels, which bring nutrients that feed tumor metabolism; metabolic changes create vulnerabilities that tumor cells adapt to (like preferring glycolysis); immune infiltration triggers PD-L1 upregulation, which protects tumor cells, etc. Recent high-throughput studies confirm that despite extensive intratumoral heterogeneity in mutations, these fundamental pathways remain recurrently perturbed in RCC (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), making them attractive targets for therapy and biomarkers for disease monitoring.

Disease Progression and Pathophysiological Sequence

RCC development typically follows a multi-stage progression:

  • Initiation: A triggering genetic event in a healthy renal epithelial cell provides the first growth advantage. In sporadic ccRCC, this is most often a “first hit” mutation in one VHL allele, followed by loss of the second allele (consistent with Knudson’s two-hit hypothesis) (pmc.ncbi.nlm.nih.gov). This can occur via somatic mutation or 3p deletion that removes the VHL locus (pmc.ncbi.nlm.nih.gov). In hereditary cases (Von Hippel–Lindau disease), a germline VHL mutation is present in every cell (first hit) and a somatic second hit in a renal cell precipitates a tumor focus (pmc.ncbi.nlm.nih.gov). For papillary RCC, initiation might be a MET mutation or trisomy of chromosome 7; for chromophobe RCC, perhaps early loss of multiple chromosomes (causing haploinsufficiency of critical genes) is the initiating event.

  • Clonal Expansion: The cell with the initiating mutation begins to proliferate abnormally, forming a neoplastic clone in the kidney tubular epithelium (often the proximal convoluted tubule, UBERON:0001285, for ccRCC and Type 2 pRCC; distal nephron for chromophobe). Early on, the VHL-mutant clone (in ccRCC) experiences constitutive HIF activation, leading to a highly vascular microtumor. This gives the small tumor adequate oxygen and nutrient supply via new capillaries (i.e., angiogenic switch turned on at inception). Over time, additional driver mutations accumulate in subsets of cells within the tumor – an evolutionary process generating subclones. Common second hits in ccRCC impact PBRM1, SETD2, or BAP1 (pmc.ncbi.nlm.nih.gov). The sequence can influence tumor behavior: for example, if a VHL-mutant cell acquires a PBRM1 mutation, the resulting clone might grow relatively slowly (indolent path); if instead it acquires BAP1 mutation, the clone may gain more aggressive traits (high grade, propensity to metastasize) (pmc.ncbi.nlm.nih.gov). This concept is supported by studies showing BAP1-mutant tumors often present with higher grade and worse outcomes than PBRM1-mutants (pmc.ncbi.nlm.nih.gov). In papillary RCC, after the MET-driven initiation, additional changes like CDKN2A loss or SETD2 mutation can likewise drive progression to higher grade tumors (pmc.ncbi.nlm.nih.gov).

  • Local Growth and Angiogenesis: As the tumor expands in the kidney, it typically remains encapsulated by the renal capsule initially (Stage I or II if >7cm). Pathophysiologically, the expanding RCC often invades into nearby structures as it grows: it can break through the tubular basement membrane, invade the renal parenchyma and vasculature. A striking feature of RCC is its tendency to invade veins – RCC can grow as a tumor thrombus in the renal vein and even extend up the inferior vena cava in advanced cases (this happens because RCC tumor cells find the low-resistance venous space conducive, often facilitated by MMPs and VEGF-induced vessel remodeling). Locally, the tumor induces a fibrous pseudo-capsule and areas of necrosis if outgrowing blood supply. Immune cells infiltrate the tumor margins, sometimes forming lymphoid aggregates – an ongoing battle between tumor and host immune surveillance.

  • Invasion and Metastasis: Key changes that facilitate metastasis include epithelial-mesenchymal transition (EMT) program activation (some RCCs with sarcomatoid differentiation show EMT-like gene expression), secretion of proteases (to degrade extracellular matrix), and continued angiogenesis to enter blood vessels. RCC commonly metastasizes hematogenously. The most frequent metastatic sites are the lungs (approximately 50–70% of metastases), bone (~30%), liver (~20%), and brain (~8%), as well as unusual sites like thyroid or skin (pmc.ncbi.nlm.nih.gov). The propensity for these sites is partly anatomical (kidney’s high blood flow to lungs) and partly molecular (e.g., CXCR4 chemokine receptor on RCC cells aiding in homing to CXCL12-rich organs like lung and bone). Notably, RCC metastases can be highly vascular lesions too (bleeding risks in lung or bone lesions). The time to metastasis can be variable – about 10% of patients have metastatic disease at diagnosis, and another ~10–20% of initially localized RCC will later metastasize (pmc.ncbi.nlm.nih.gov). Clinically and pathologically, progression is captured by staging (I–IV) and grading systems (historically Fuhrman grade, now WHO/ISUP nucleolar grade). A higher grade reflects more anaplasia, often correlating with molecular changes like TP53 mutations or sarcomatoid morphology. Over the course of progression, RCC cells also often upregulate immune checkpoints (e.g., PD-L1 expression is higher in more advanced or sarcomatoid tumors), helping later-stage tumors to resist immune destruction (pmc.ncbi.nlm.nih.gov).

  • Tumor Heterogeneity: A hallmark of RCC progression is branching evolution leading to intratumor heterogeneity (ITH). Different regions of a single RCC may harbor distinct mutations and phenotypes (e.g., one region might have PBRM1 mutation, another BAP1, etc.). This results in spatial niches – e.g., hypoxic necrotic center vs. proliferative invasive edge (pmc.ncbi.nlm.nih.gov). The tumor edge tends to have more proliferative activity (high Ki-67 index) than the center (pmc.ncbi.nlm.nih.gov), possibly driven by better oxygenation at the periphery and signaling crosstalk with the surrounding stroma. Interestingly, recent evidence suggests that not all genetic mutations have an obvious “functional proxy” at the phenotypic level due to compensatory mechanisms and ITH (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This complexity means that as RCC progresses, different clones can dominate different metastases or recur after treatment, which is a major challenge for therapy (leading to mixed responses and drug resistance).

  • Late Progression and Resistance: In advanced metastatic RCC, additional molecular changes often emerge under therapeutic pressure. For instance, prolonged anti-angiogenic therapy can lead tumors to activate alternative angiogenic pathways or become more invasive. Some RCCs undergo dedifferentiation to spindle-cell or sarcomatoid carcinoma, which is associated with TP53 mutations and aggressive behavior (this can be viewed as progression to a higher-grade state with loss of original differentiation). RCC can also seed renal vein tumor thrombi, which if it propagates can cause Budd-Chiari syndrome or pulmonary emboli (though tumor thrombi are solid). Ultimately, widespread metastases lead to organ dysfunction (e.g., lung failure, bone marrow replacement, etc.). Cachexia (weight loss and muscle wasting, HP:0004326) is common in late stages, likely driven by tumor-secreted cytokines like IL-6 and TNF-α.

In summary, RCC progression is stepwise: initiation (often VHL loss) → clonal expansion with angiogenesis → additional hits (PBRM1/BAP1 etc.) → local invasion (driven by molecular changes and microenvironment interactions) → metastasis (via hematogenous spread, facilitated by EMT and angiogenesis) → therapy resistance and further clonal evolution. These stages align with clinical phases from an incidentally detected small tumor to symptomatic advanced disease. The multi-stage model is supported by molecular timing studies (e.g., TRACERx Renal) which found that the 3p loss event often occurs years before clinical presentation, with subsequent driver mutations accruing over time (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). By the time RCC is diagnosed, it may already be an assembly of subclones at various stages of this evolutionary path.

Phenotypic Manifestations and Clinical Correlations

The disrupted molecular and cellular processes in RCC manifest as specific clinical phenotypes (Human Phenotype Ontology terms) and pathological features:

  • Solid Renal Mass on Imaging: Most RCCs today are discovered incidentally as an asymptomatic renal mass on ultrasound or CT scan (pmc.ncbi.nlm.nih.gov). The tumor’s hypervascularity often leads to radiologic contrast enhancement. Smaller tumors are often asymptomatic (hence the high rate of incidental detection, ~37–61% (pmc.ncbi.nlm.nih.gov)). As a mass grows, it can cause the classic triad of flank pain (HP:0003418), hematuria (HP:0000790), and a palpable abdominal mass – however, this triad is now uncommon (<10% of cases) (pmc.ncbi.nlm.nih.gov). Hematuria results from tumor invasion into the collecting system or renal pelvis, causing bleeding into the urine. Flank pain can result from tumor stretching the renal capsule or invading local nerves, or from hemorrhage into the tumor causing capsular distension. A palpable mass indicates a relatively large tumor typically (> T2 stage). Gross hematuria occurs in <25% of patients at diagnosis and usually indicates tumor involving the urinary collecting system or advanced disease (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

  • Paraneoplastic Syndromes: RCC is notorious for causing systemic manifestations unrelated to tumor burden (occurring in ~10–40% of patients) (pmc.ncbi.nlm.nih.gov). These paraneoplastic syndromes (HP:0002665) reflect ectopic production of hormones or cytokines by the tumor:

  • Erythrocytosis (Polycythemia, HP:0001901): 2–5% of RCC patients develop elevated red blood cell counts (pmc.ncbi.nlm.nih.gov). Mechanism: RCC cells (especially VHL-deficient ones) overexpress EPO (erythropoietin) under control of HIF-2α (pmc.ncbi.nlm.nih.gov). The excess EPO stimulates red blood cell production, leading to ruddy complexion, high hemoglobin, and sometimes hyperviscosity symptoms. This is a direct result of the HIF pathway activation in tumor cells.
  • Paraneoplastic Hypercalcemia (HP:0003072): Up to 20–30% of advanced RCC can have high calcium levels (pmc.ncbi.nlm.nih.gov). Mechanisms: some RCC produce parathyroid hormone-related peptide (PTHrP) which causes calcium release from bone; additionally, extensive osteolytic bone metastases (common in RCC) can exacerbate hypercalcemia. Clinically, this leads to fatigue, confusion, and polyuria/polydipsia.
  • Non-metastatic Hepatic Dysfunction (Stauffer syndrome): ~3% of RCC patients present with cholestatic liver dysfunction (elevated alkaline phosphatase, hepatosplenomegaly) in the absence of liver metastases (pmc.ncbi.nlm.nih.gov). This is thought to be due to cytokines (like IL-6 or tumor necrosis factor) released by the tumor affecting the liver. Stauffer syndrome can cause jaundice and coagulopathy, but interestingly it often reverses after nephrectomy or effective treatment (pmc.ncbi.nlm.nih.gov), confirming its paraneoplastic nature.
  • Anemia and Cachexia: Anemia (low RBC count) is reported in 20–50% of RCC (pmc.ncbi.nlm.nih.gov), often anemia of chronic disease from inflammation (elevated IL-6 drives hepcidin up, reducing iron availability). This coexists paradoxically with erythrocytosis in some patients (different clones might produce EPO vs. IL-6). Cachexia (weight loss, muscle wasting) is common in advanced RCC due to tumor-produced pro-inflammatory cytokines (IL-6, TNF-α, etc.) and can be severe, contributing to fatigue and weakness.
  • Fever and Night Sweats: Low-grade fever (in about 8% of patients) (pmc.ncbi.nlm.nih.gov) and drenching sweats can occur due to cytokine release (RCC was historically known as a cause of “fever of unknown origin”). IL-6 is again a suspected mediator, and successful treatment often abates these fevers.

  • Thrombocytosis (high platelets): 8–12% of patients (pmc.ncbi.nlm.nih.gov) have elevated platelet counts, likely from IL-6 driven megakaryocyte stimulation. This can increase risk of venous thromboembolism in an already pro-thrombotic malignancy.

  • Hypertension (HP:0000822): Approximately 15–20% of RCC patients have new-onset or worsening high blood pressure (pmc.ncbi.nlm.nih.gov). This can be multifactorial: renal tumors can overproduce renin (rarely), but more commonly chronic kidney disease due to tumor or nephrectomy plays a role, and high circulating VEGF can increase endothelial dysfunction. Also, anti-VEGF therapies for RCC cause hypertension as a side effect by decreasing nitric oxide in vessels (pmc.ncbi.nlm.nih.gov). In some cases, removing the kidney tumor (nephrectomy) actually improves blood pressure, implying a tumor-secreted pressor substance.

  • Macroscopic Pathology: RCC tumors are typically golden-yellow (due to high lipid content in clear cells) with areas of hemorrhage and necrosis. The clear cells have a high glycogen and cholesterol content (reflecting metabolic changes). Papillary RCC often appears tan-brown and is softer, with frequent hemorrhagic cystic areas and papillary structures microscopically. Chromophobe RCC is a pale beige-tan and has distinct plant-cell-like histology with prominent cell membranes and perinuclear halos (due to abnormal mitochondria). The pathophysiology (lipid accumulation in clear cell, papillae formation in papillary, etc.) directly correlates with these appearances – e.g., clear cells accumulate lipids because of HIF-driven lipid uptake and abnormal metabolism; papillary tumors form papillae likely due to their cell of origin (distal convoluted tubule epithelium) and growth pattern.

  • Histological Phenotypes: On microscopy, ccRCC cells have clear cytoplasm because glycogen and lipid are dissolved on slide prep – a key phenotypic hallmark linked to the metabolic reprogramming discussed. They also often express carbonic anhydrase IX (CAIX) diffusely on immunohistochemistry (pmc.ncbi.nlm.nih.gov), a direct HIF1 target and diagnostic marker of ccRCC. Papillary RCC cells often have eosinophilic cytoplasm and grow in a papillary architecture with fibrovascular cores; type 1 papillary has small basophilic cells (often MET-driven, indolent), while type 2 has large eosinophilic cells (often FH or other mutations, aggressive). Chromophobe RCC cells are polygonal with pale/reticulated cytoplasm and a perinuclear clearing; they often show multiple chromosomal losses cytogenetically, explaining the “chromophobic” (pale) appearance due to loss of pigmentation organelles and other molecules. Each subtype’s phenotype reflects its genotype: e.g., FH-mutant RCC (HLRCC) often has intensely eosinophilic, large cells with massive nuclei (very high-grade appearance), corresponding to its highly deranged metabolism and aggressive behavior.

  • Symptomatology of Metastases: Metastatic spread produces symptoms based on organ involved. Lung metastases (most common) cause cough, hemoptysis, or dyspnea. Bone metastases cause bone pain (HP:0002653) and pathologic fractures; RCC bone lesions are often osteolytic (consistent with hypercalcemia). Brain metastases cause headaches, seizures, or focal neurologic deficits. Occasionally, unusual sites like thyroid metastases may present as a thyroid nodule, etc. RCC’s ability to metastasize widely is due to its rich blood supply and expression of adhesion molecules enabling tumor cell lodging in various tissues. Because RCC metastases can appear years after nephrectomy (even >5–10 years later in some cases), long-term follow-up is needed – reflecting that dormant microscopic metastatic clones can exist and later get activated.

  • Laboratory and Biomarker Correlations: Aside from clinical phenotypes, certain lab abnormalities mirror the pathophysiology: Elevated serum LDH and C-reactive protein (CRP) are adverse prognostic markers in RCC, indicating high tumor metabolic activity (LDH from high glycolysis) and inflammation (CRP from IL-6). These are included in prognostic risk scores (pmc.ncbi.nlm.nih.gov). High serum CAIX or VEGF levels can sometimes be detected and correspond to tumor burden/angiogenesis, though they are not used routinely. Molecular signatures (mRNA expression profiles) have identified subsets of ccRCC, such as an “angiogenic” subtype vs. an “immune” subtype, linking phenotype to dominant pathophysiology: e.g., tumors with high VEGF and angiogenesis genes (often PBRM1-mutant) versus tumors with high immune checkpoint expression and inflammation (often BAP1-mutant) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These differences manifest clinically in how tumors appear on scans (more vs. less enhancement), their growth rate, and their response to therapies (angiogenesis-high tumors respond well to VEGF inhibitors, immune-high tumors may respond better to immunotherapy).

In conclusion, the clinical phenotype of RCC – from asymptomatic small tumor to systemic paraneoplastic syndromes – is intimately tied to its underlying molecular pathology. The angiogenic drive explains its vascular nature and imaging appearance; the metabolic shifts explain the clear cell morphology and systemic effects (weight loss, etc.); the ectopic hormone production explains syndromes like erythrocytosis and hypercalcemia; and the immune evasion explains why immunotherapy is needed for cure in many advanced cases. Clinicians leverage this knowledge: for example, the presence of paraneoplastic syndromes or certain lab changes can hint at RCC even before imaging confirms it, and conversely effective treatment often leads to resolution of these syndromes (a striking validation of the causal pathophysiology) (pmc.ncbi.nlm.nih.gov).

Recent Developments and Expert Insights

Advances in the past few years have deepened our understanding of RCC pathophysiology and led to new interventions:

  • Molecular Subclassification: The 2022 WHO classification of renal tumors now recognizes over 20 subtypes of RCC, many defined by specific molecular alterations (pmc.ncbi.nlm.nih.gov). For example, FH-deficient RCC, SDH-deficient RCC, TFE3/Xp11 translocation RCC, and others are distinguished by unique pathogenesis. This granularity ensures patients receive tailored surveillance and therapy (e.g., FH-deficient RCC mandates aggressive treatment even if the tumor is small, due to high metastatic potential (pmc.ncbi.nlm.nih.gov)).

  • Targeted Therapies Evolving: Building on the VHL/HIF pathway knowledge, HIF2α inhibitors (like belzutifan) have emerged. As of 2023, belzutifan showed a 22% response rate in refractory metastatic RCC and significantly prolonged progression-free survival compared to an mTOR inhibitor (www.merck.com). This drug, by directly blocking the HIF transcriptional driver, represents a new class of therapy directly addressing RCC’s core pathophysiology. Similarly, MET inhibitors (e.g., savolitinib) are being tested in MET-driven papillary RCC and showing promise (early trials indicate objective responses, particularly in MET-mutated tumors). Combination therapies are also a focus: e.g., combining glutaminase inhibitors with immunotherapy to exploit metabolic vulnerabilities while stimulating immune attack (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

  • Immune Microenvironment Research: Cutting-edge single-cell sequencing and high-plex imaging of RCC tumors have mapped the immune landscape in fine detail. A 2022 study by De Filippis et al. identified distinct immune microenvironment patterns in ccRCC, such as an “immune-inflamed, exhausted T-cell” niche vs. an “immune-cold, angiogenic” niche (pmc.ncbi.nlm.nih.gov). These correlate with mutations (e.g., PBRM1-mutant tumors were more immune-infiltrated in some reports) and could guide immunotherapy use. Moreover, novel immunotherapies beyond PD-1 are in trials (e.g., HIF-2α inhibitors combined with PD-1 blockade, CAR-T cells targeting CAIX or other RCC antigens, etc.).

  • Genomic Heterogeneity and Precision Medicine: The TRACERx Renal consortium (Turajlic et al., 2018) provided detailed timelines of RCC evolution. One striking finding was that the average ccRCC has ~4 driver events, and if a clone acquires all needed drivers early (VHL, + others), it can metastasize rapidly, whereas if evolution is more branched, metastasis may occur later or not at all (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). This is spawning research into molecular prognostics: for example, testing tumors for co-mutations like BAP1 vs. PBRM1 can stratify patients’ risk of aggressive disease (pmc.ncbi.nlm.nih.gov). Efforts are underway to integrate genomic data with clinical nomograms to enhance prognostic scoring and perhaps to allocate therapies (though, as one 2023 study cautioned, genotype-phenotype correlations aren’t always straightforward due to functional heterogeneity (pmc.ncbi.nlm.nih.gov)).

  • Expert Commentary: In a 2019 Nature Reviews piece, Dr. Robert Motzer and colleagues described RCC’s therapeutic progress as moving “from the dark age to the golden age” (pmc.ncbi.nlm.nih.gov), thanks to pathophysiology-driven drug development. They highlight that understanding VHL/HIF led to VEGF inhibitors, understanding immune evasion led to checkpoint inhibitors, and ongoing research into metabolism and epigenetics will likely yield the next breakthroughs (pmc.ncbi.nlm.nih.gov). Reflecting on combination therapies, experts note that current first-line regimens (PD-1 immunotherapy + VEGF-TKI) are effectively targeting both the immune system and angiogenesis – tackling two key hallmarks of RCC (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Nonetheless, they also emphasize that cures are elusive in metastatic RCC; thus, research is focusing on overcoming resistance (e.g., preventing or rechallenging VEGF resistance by alternating therapies, targeting T cell exhaustion pathways, etc.).

  • Statistics and Outcomes: Epidemiologically, RCC incidence worldwide continues to rise slowly (~1–2% per year), but mortality is dropping (~2% per year in the US) (pmc.ncbi.nlm.nih.gov), which is attributed to earlier detection and better therapies. In 2023, an estimated 81,800 new RCC cases were diagnosed in the US (pmc.ncbi.nlm.nih.gov). The 5-year survival for localized RCC (confined to kidney) exceeds 90%, while for metastatic RCC it remains around 13%–30% in modern series (pmc.ncbi.nlm.nih.gov). The pathophysiological understanding has directly contributed to this improvement: for example, adjuvant immunotherapy (pembrolizumab) after nephrectomy improves disease-free survival in high-risk cases (pmc.ncbi.nlm.nih.gov), and this strategy stems from recognizing that micrometastatic RCC can be tackled by ramping up the immune system early.

In summary, renal cell carcinoma pathophysiology encompasses a web of molecular and cellular derangements – principally involving hypoxia sensing, angiogenesis, chromatin/tumor suppressor alterations, metabolic shifts, and immune interactions – that together drive the initiation, growth, and spread of the tumor. Our current treatments (surgery, VEGF inhibitors, mTOR inhibitors, immune checkpoint blockers, HIF2 inhibitors, etc.) are all rooted in these pathogenic mechanisms. Ongoing research (with an emphasis on 2023–2024 findings) is further unraveling RCC’s complexity, aiming to personalize therapy (based on genetic drivers and immune profile) and improve outcomes. As one recent review noted, “insights into the molecular pathogenesis of RCC have led to the development of therapies that target its underlying pathophysiology and immunobiology” (pmc.ncbi.nlm.nih.gov), a testament to how understanding disease mechanisms translates into clinical advances. Each new discovery – whether a gene mutation, a metabolic dependency, or an immune escape mechanism – adds a piece to the puzzle, bringing us closer to fully conquering this challenging cancer.

References:

  1. Rose TL & Kim WY. Renal Cell Carcinoma. JAMA. 2024;332(12):1001–1010. PMID: 39196544 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (Key review of RCC epidemiology, genetics, pathophysiology, and treatment)
  2. Nabi S et al. Renal cell carcinoma: a review of biology and pathophysiology. F1000Research. 2018;7:307. PMID: 29568504 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (Detailed review of RCC genetic alterations, VHL/HIF pathway, and immune environment)
  3. Turajlic S et al. Tracking renal cancer evolution (TRACERx Renal). Cell. 2018;173(3):595-610.e11. PMID: 29625050 (pubmed.ncbi.nlm.nih.gov). (Study of ccRCC intratumoral heterogeneity and evolutionary trajectories, highlighting ubiquitous 3p loss and subclonal diversification)
  4. Rhoades Smith KE & Bilen MA. A review of papillary renal cell carcinoma and MET inhibitors. Kidney Cancer. 2019;3(3):151–161. PMID: 31867475 (pmc.ncbi.nlm.nih.gov). (Overview of papillary RCC subtypes, MET-driven pathogenesis, and targeted therapies)
  5. Sudarshan S et al. Fumarate hydratase deficiency in renal cancer induces HIF-1α stabilization by ROS. Mol Cell Biol. 2009;29(15):4080–4090. PMID: 19470762 (pmc.ncbi.nlm.nih.gov). (Experimental study showing how FH loss leads to pseudohypoxia and metabolic reprogramming in RCC)
  6. Choueiri TK et al. Belzutifan for VHL disease-associated RCC and advanced RCC. – FDA Approval Press Release, Dec 14, 2023 (www.merck.com) (www.merck.com). (Announces HIF-2α inhibitor approval; contains expert commentary on its significance)
  7. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell RCC. Nature. 2013;499(7456):43–49. PMID: 23792563 (pmc.ncbi.nlm.nih.gov). (Landmark TCGA study defining the key mutated genes and pathways in ccRCC)
  8. Şenbabaoğlu Y et al. Tumor immune microenvironment in ccRCC: prognostic mRNA signatures. Genome Biol. 2016;17:231. PMID: 27884208 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (Genomic analysis linking immune infiltration patterns with outcomes in RCC)
  9. Brugarolas J. PBRM1 and BAP1 as novel targets for RCC. Cancer J. 2013;19(4):324–332. PMID: 23989106 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (Discusses PBRM1/BAP1 tumor suppressors and their clinical impact in RCC)
  10. Linehan WM & Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol. 2013;23(1):46–55. PMID: 23123217. (Explores how metabolic alterations like VHL/HIF, FH, SDH drive RCC; introduces concept of oncometabolites)

(All links and citations accessed 2023–2024; URLs provided where applicable. Dates in references indicate publication year.)